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ABSTRACT 
Inflammation plays a key role in tumor promotion and development. 
Indeed, high levels of cyclooxygenase-2 (COX-2) expression are 
associated with worse prognosis in several types of cancer including 
melanoma. The aim of our project, divided in three sections, has been 
to investigate on the role of COX-2 in melanoma development and 
progression. In the first phase of the project, we evaluated the 
expression of both COX-1 and COX-2 in a large panel of human 
melanoma cells and assessed the effect of COX-2 ablation on cancer cell 
proliferation and invasiveness by the mean of siRNA technology and by 
selective inhibition of COX-2 activity. Translation of in vitro data to in 
vivo models of cutaneous melanoma showed that in COX-2-/- mice tumor 
development was almost blunted as compared to littermate control 
C57Bl/6J. Finally, we performed a retrospective clinical study on 45 
human lymph node melanoma metastases and correlated COX-2 
expression to progression free survival (PFS). Our results show an 
inverse correlation between PFS and COX-2 expression suggesting that 
COX-2 is a negative prognostic factor in metastatic melanoma.   
In addition to COX enzymes, also hydrogen sulfide (H2S), an endogenous 
gasotransmitter, has been recently demonstrated to be involved in 
human melanoma. Thus, the second phase of the project was focused 
on the evaluation of the efficacy of a new H2S-releasing nonsteroidal 
anti-inflammatory drugs (H2S-NSAIDs) named ATB-346, developed by 
combining naproxen with a chemical moiety that donates hydrogen 
sulfide. In particular, we used cell culture and a murine melanoma 
model to evaluate the effect of ATB-346 on: i) proliferation of human 
melanoma cells; ii) melanoma development in mice. Cell culture studies 
demonstrated that ATB-346 reduced the proliferation of human 
melanoma cells and this effect was associated to induction of apoptosis 
and inhibition of NF-κB activation. Moreover in vivo data showed that 
ATB-346 significantly reduced melanoma development. In conclusion, 
by using this dual approach we propose that COXs and H2S pathway 
could be innovative therapeutic targets to generate new treatment 
options based on “combination therapy” for melanoma. 
Finally, in the third and last phase of the project, we decided to better 
define the role of COX-2 in melanoma development. The aim was to 
establish if this enzyme acts predominantly in the microenvironment 
rather than in tumor cells. For this purpose we deleted COX-2 in 
B16/F10 murine melanoma cells by the mean of CRISPR/Cas9 
technology. We firstly investigated on the effect of COX-2 knockdown 
on proliferation, migration, invasion and colonie formation of B16/F10 
murine melanoma cells. In vitro studies demonstrated that 
CRISPR/Cas9-mediated COX-2 knockdown decreased proliferation of 
B16/F10 cells and inhibited some features of metastatic melanoma such 
as motility, invasiveness and focus formation. Finally, subcutaneously 
injection of B16/F10 cells knocked down for COX-2 showed slightly 
reduced melanoma growth and reduced the CXCL1 chemokine plasma 
levels. In addition, we also investigated on the expression and role of 
miR-143-3p in human malignant melanoma that has been shown to be 
dysregulated in many cancers. Our results showed that the expression of 
miR-143-3p was lower in human melanoma cells, as well as human 
tumor biopsy specimens, when compared to normal human 
melanocytes. Ectopic expression of miR-143-3p in human melanoma 
cells inhibited proliferation, migration, invasion and promoted apoptosis 
acting through a molecular mechanism that, at least in part, is 
dependent on inhibition of the COX-2 gene. Collectively, our findings 
show that COX-2 has a critical role in modulating melanoma 
development and progression. Nonetheless, significant challenges still 
lie ahead for blocking the interactions between the microenvironment 
and tumors. 
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CHAPTER 1: INTRODUCTION 
1.1  INFLAMMATION AND CANCER 
1.1.1 The inflammatory pathway 
Inflammation is a protective response involving host cells, blood vessels, 
proteins and other mediators that is intended to eliminate the initial 
cause of cell injury, as well as the necrotic cells and tissues resulting 
from the original insult, and to initiate the process of repair [1]. The first 
description of inflammation by Cornelius Celsus in the 1st century, 
defined the four cardinal signs of inflammation: heat (calor), redness 
(rubor), swelling (tumor), pain (dolor), and loss of function (functio 
laesa) then added by Rudolf Virchow in the 19th century [2]. 
Inflammation is often considered in terms of acute inflammation and 
chronic inflammation that differ in onset, cellular infiltrate and local and 
systemic signs [3]. The acute inflammatory response follows within 
seconds of the tissue injury and lasts for some minutes inducing 
vasodilation and increase of capillary permeability which allows to 
augment the blood flow and entry of fluids and diffusible components 
to the infected area inducing redness and erythema as consequence. 
This phase usually terminates after several tens minutes and is common 
in case of minor injuries such as bruising, scratching, cuts, and 
abrasions. If there has been sufficient damage to the tissues, or if 
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infection has occured, the acute inflammatory response takes place 
over the next few hours.  
In this phase there is the recruitment of leukocytes, particularly 
neutrophils, in the tissues [4]. The sequence of events in the 
recruitment and activation of leukocytes consists of different phases: 
first leukocytes accumulate themselves to the endothelial cells 
(margination), then begin to tumble on the endothelial surface by the 
interaction between adhesion molecules expressed on the surface of 
both leucocytes and endothelial cells (rolling and adhesion) and then 
migrate through the vessels and move toward sites of infection or injury 
(diapedesis and chemotaxis). Finally leukocytes bind and ingest most 
microorganisms and dead cells (phagocytosis) and the subsequent 
resolution process begins restoring the normal tissue architecture [5]. If 
the acute inflammatory response fails to eliminate the pathogen, a 
chronic inflammatory state ensues where the inflammatory process 
persists and acquire new characteristics. Here the neutrophil infiltrate is 
replaced with macrophages, lymphocytes and plasma cells producing 
inflammatory cytokines, growth factors and enzymes which in turn 
contribute to the progression of tissue damage and secondary repair 
including fibrosis and granuloma formation. 
There are two types of chronic inflammation:  
Non specific proliferative: characterized by the presence of non-specific 
granulation tissue formed by infiltration of mononuclear cells 
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(lymphocytes, macrophages, plasma cells) and proliferation of 
fibroblasts, connective tissue, vessels and epithelial cells, for example, 
an inflammatory polyp-like nasal or cervical polyp and lung abscess.  
Granulomatous inflammation: A specific type of chronic inflammation 
characterized by the presence of different nodular lesions or 
granulomas formed with a conglomeration of activated macrophages or 
its derived cells called epithelioid cells usually enclosed by lymphocytes. 
The macrophages or epithelioid cells inside the granulomas often 
combine to form Langhans or giant cells such as foreign body, Aschoff, 
Reed-Sternberg and Tumor giant cells.  
There are two major types of granuloma: 
Foreign body granuloma: that are formed to a foreign body or T-cell 
mediated immune response such as in sarcoidosis and Crohn’s disease 
[6, 7].  
Infectious granuloma: Granuloma that are formed from chronic 
infection such as in tuberculosis and leprosy [8].  
Although chronic inflammation progresses silently, it is the cause of 
most chronic diseases including obesity, type 2 diabetes, 
atherosclerosis, asthma and neurodegenerative diseases [9]. 
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1.1.2 Inducers and sensors of inflammation 
A typical inflammatory response consists of four components: inducers, 
sensors, mediators and the effectors of inflammation. There are 
different inducers that trigger the inflammatory response. They activate 
specific sensors, which then stimulate the production of distinct sets of 
mediators. Inducers of inflammation can be divided in exogenous or 
endogenous [10].  
Exogenus stimuli are both microbial and non-microbial, such as 
pathogen-associated molecular patterns (PAMPs) and virulence factors. 
PAMPs are a restricted and specific set of conserved molecular patterns 
that are carried by all microorganisms and are recognize by the host 
through the expression of a specific set of receptors known as pattern-
recognition receptors (PRRs) [11]. The second class of microbial inducers 
are virulence factors that are not recognized by specific receptors but by 
specialized sensors such as NACHT-, leucine-richrepeat-and pyrin-
domain-containing protein (NALP3) inflammasome [12]. Non-microbial 
exogenous stimuli are allergens, irritants, foreign bodies and toxic  
compounds that simulate the virulence activity of parasites or can act as 
irritants on the mucosal epithelia [1]. Others exogenous stimuli are: 
physical (such as extremely low or high temperature or ionizing 
radiations) and nutritive (e.g. deficiency of oxygen and vitamins). 
Endogenous stimuli are signals generated by damaged or stressed 
tissues. For example, the release of ATP and high-mobility group box 1 
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protein (HMGB1) during necrotic death cells, can cooperate with Toll-
like receptors (TLRs) to induce an inflammatory response [13]. Or, the 
formation of urate and calcium crystals that are common in people-
eating high purine foods and are responsible of periarticular diseases 
like gout and pseudogout [14]. These crystals are detected by 
macrophages activating the NALP3 inflammasome which in turn 
activates the production of caspase-1 substrates and members of the 
interleukin 1 (IL-1) family [15]. 
Pattern-recognition receptors are designed to sense the presence of 
infectious pathogens and substances released from dead cells. 
Currently, four different classes of pattern-recognition receptors 
families have been identified: Toll-like receptors (TLRs), C-type lectin 
receptors (CLRs), the Retinoic acid-inducible gene (RIG)-I-like receptors 
(RLRs) and NOD-like receptors (NLRs) [16].  
TLRs are one of the best-characterized PRRs and are responsible for 
sensing invading pathogens outside of the cell and in intracellular 
endosomes and lysosomes [17]. TLRs are expressed by T cells, B cells 
neutrophils, mast cells, monocytes and macrophages. There are ten 
mammalian TLRs, TLR1 –TLR10, which recognize products of bacteria 
(such as endotoxin and bacterial DNA), viruses (such as double stranded 
RNA), and other products including lipoproteins and di- and triacyl 
lipopeptides, fungal zymosan, peptidoglycans, flagellin and different 
synthetic molecules such as imidazoquinolines and guanosine 
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analogues. These molecules are recognized by distinct TLRs in 
combination with coreceptors, or by TLR heterodimers [18]. TLR1 is 
closely related to TLR2 and TLR6 with which it forms heterodimers that 
recognize bacterial lipoproteins and lipopeptides [19]. TLR4 recognizes 
lipopolysaccharides (LPS), which are present in the cell wall of Gram-
negative bacteria [20]. The TLR5 recognizes flagellin the dominant 
component of the bacterial flagellum and the structure responsible for 
motility in different bacterial species [21]. TLR3, TLR7, TLR8, and TLR9 
are different from other TLRs since they are not expressed at the cell 
surface but located in endosomal compartment. TLR3, TLR7, and TLR8 
detect double- and single-stranded RNA and TLR9 detects unmethylated 
CpG DNA [22]. Finally, TLR10 is the only remaining orphan receptor 
without a known ligand or signaling function. Moreover, it has been 
recently reported that TLR10 does not activate the immune system and 
has instead been shown to suppress inflammatory signaling on primary 
human cells [23]. 
TLRs signaling is divided into two distinct pathways: the myeloid 
differentiation primary response 88 (MyD88) and TIR-domain-containing 
adapter-inducing interferon-β (TRIF) (Figure 1.1). Those signaling 
pathways lead to activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-𝜅B) protein, that induces transcription 
of a wide range of genes involved in the inflammatory response 
including cytokines, chemokines, and immunoreceptors [24].  
INTRODUCTION 
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Figure 1.1: TLR and NLR signaling pathways [25] 
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MyD88 is utilized by all TLRs with the exception of TLR3 and drives NF-
𝜅B and mitogen-activated protein kinase (MAPK) activation to control 
inflammation. TRIF, also known as TICAM1, is utilized by TLR3 and TLR4 
and is triggered by dsRNA and LPS, respectively [26]. 
CLRs are crucial for controlling both innate and adaptive immune 
response and are expressed by dendritic cells (DCs), monocytes and 
macrophages [16]. CLRs recognize carbohydrates, such as mannose, 
fucose, and glucan carbohydrate structures present in bacterial, viral, 
and fungal components. 
RLRs are intracellular receptors for virus recognition. There are three 
major components of this family: retinoic acid-inducible gene I (RIG-I), 
melanoma differentiation factor-5 (MDA5), and laboratory of genetics 
and physiology-2 (LGP-2) that bind to virus double-stranded RNA. 
Activation of RIG-I and MDA5 increase the secretion of type I interferons 
(IFNs), such as IFN-β, through the activation of the IFN regulatory factor 
3 (IRF3) transcription factor [27]. Conversely, LGP-2 has a negative 
regulatory role by inhibiting IRF3 and the secretion of IFN-β. 
In addition to sensing of microbial RNAs by RLRs, STING signaling is a 
recent identified pathway that recognize microbial and self-DNA [28]. 
STING (Stimulator of Interferon Genes, also known as MITA, ERIS, MPYS, 
or TMEM173) is thought to function as an adaptor protein, which links 
upstream DNA sensors to downstream IRF-3 and NF-κB pathway 
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activation inducing the expression of IFNs and inflammatory cytokines 
such as TNF, IL-1β, and IL-6 [29]. 
NLRs are intracellular sensors localized in the cytoplasm of DCs, 
macrophages and lymphocytes and are associated with cell stress. There 
are different members of this family, in particular NOD1, NOD2, and 
NALP3 [30]. NOD1 and NOD2 recognize intracellular bacterial cell 
products in both Gram-positive and Gram-negative bacteria driving the 
activation of NF-𝜅B and MAPK pathways, leading to proinflammatory 
cytokine secretion [16]. NALP3 responds to a widest array of stimuli 
through the development, togheter with NLRP1 and NLRC4, of a 
multiprotein complex named NALP3 inflammasome (Figure 1.1) [30]. 
Inflammasome induces the cleavage and consequent activation of 
caspase-1 which in turn cleaves the precursor cytokines pro-IL-1β and 
pro-IL-18, producing the biologically active cytokines IL-1β and IL-18 and 
also inducing an inflammatory form of cell death known as pyroptosis 
[31]. IL-1β is a cytokine that promotes T helper 1 (Th1) and T helper 17 
(Th17) differentiation. IL-18 is important for IL-17 expression by Th17 
cells and for T cell polarization toward Th1 or Th2 profiles in 
combination with other cytokines [32].  
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1.1.3 Mediators of inflammation 
Inflammatory mediators are soluble, diffusible molecules that can be 
produced locally by cells at the site of inflammation or derived from 
circulating inactive precursors to be then activated at the site of 
inflammation. Some mediators (such as histamine and serotonin) are 
normally stored in intracellular granules of mast cells, basophils and 
platelets and are rapidly released upon cellular activation. Others are 
synthesized de novo or circulate as inactive precursors in the plasma 
and require a proteolytic cleavage to acquire their biological activity [1]. 
Inflammatory mediators can be divided into seven groups according to 
their biochemical properties: vasoactive amines, vasoactive peptides, 
fragments of complement components, lipid mediators, cytokines, 
chemokines and proteolytic enzymes.  
The vasoactive amines are responsible for the immediate and short-
lived responses in inflammation including vasodilation, increase of 
vascular permeability and smooth muscle contraction. Histamine and 
serotonin are the most important vasoactive amines and are secreted 
by mast cells and platelet degranulation [33]. 
Vasoactive peptides are small proteins, such as substance p that is 
stored in secretory vesicles and released by sensory neurons 
transmitting pain signals and regulating vessel tone and vascular 
permeability. Other vasoactive peptides are bradykinin, fibrinopeptide 
A, fibrinopeptide B and fibrin degradation products. Bradykinin is the 
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main product of the kallikrein–kinin cascade activated by the Hageman 
factor together to the clotting, fibrinolytic and the complement system. 
Like histamine, bradykinin increases vascular permeability, arteriolar 
dilation, and bronchial smooth muscle contraction [34]. 
The complement system consists of plasma proteins that play an 
important role in inflammation. In particular, the complement-derived 
factors C3a, C4a and C5a (also called anaphylatoxins) increase vascular 
permeability and cause vasodilation by inducing mast cells to release 
histamine, activate leukocytes, increasing their adhesion to 
endothelium, and augment the phagocytosis by neutrophils and 
macrophages [35]. 
Lipid mediators are eicosanoids and platelet-activating factor (PAF). 
Eicosanoids derived from the metabolism of arachidonic acid (AA). AA is 
a component of cell membrane phospholipids released through the 
action of phospholipase A2 (PLA2) that is activated by other 
inflammatory mediators sush as the complement-derived factor C5a 
[36]. AA is processed by two different enzimes: Cyclooxygenase (COX) 
and Lypooxigenase (LOX), which in turn produce respectively 
prostaglandins, thromboxanes and leukotrienes and lipoxins. We will 
discuss about eicosanoids and their relationship with cancer later in this 
thesis. PAF is generated by the acetylation of lysophosphatidic acid and 
acts directly on target cells through the binding with a specific G 
protein–coupled receptor. PAF stimulates platelet aggregation, causes 
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bronchoconstriction and induces a potent vasodilatation and increase of 
vascular permeability. 
Another class of inflammatory mediators are cytokines. Inflammatory 
cytokines are produced by different cell types including in particular 
macrophages and mast cells. The major cytokines involved in 
inflammation are tumour-necrosis factor-α (TNF-α), IL-1, IL-6 and many 
others [37]. TNF-α and IL-1 stimulate the expression of adhesion 
molecules on endothelial cells, increasing leukocyte binding and 
recruitment, and augment the production of additional cytokines.  
Chemokines are produced by different cell types and act as 
chemoattractants controlling extravasation and chemotaxis of 
monocytes, lymphocytes, neutrophils, eosinophils, basophils, natural 
killer cells, dendritic cells, and endothelial cells towards the site of 
inflammation [38]. 
Proteolytic enzymes have different roles in inflammation. In particular 
elastase, collagenase, and cathepsin, secreated by neutrophils and 
monocytes, destroy phagocytosed substances. Their activity is regulated 
by antiproteases present in the plasma and tissue fluids such as α1-
antitrypsin and α2-macroglobulin.  
In addition, other mediators of inflammation are: reactive oxygen 
species (ROS) and nitric oxide (NO).  
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ROS are released from neutrophils and macrophages and amplify the 
cascade of inflammatory mediators by inducing adhesion molecule 
expression, chemokines and cytokines promoting their migration across 
the endothelial barrier helping also in the clearence of phagocytosed 
microbes and necrotic cells [39].  
NO is a soluble gasotransmitter that possesses cytotoxic properties 
serving as a killing mechanism against invading microbes. In particular, 
macrophages produce it as cytotoxic agent for killing microbes and 
tumor cells [40].  On the other hand, NO is considered as a pro-
inflammatory mediator that induces inflammation due to over 
production in unusual conditions such as in inflammatory disorders of 
the joint, lungs and gut [41]. 
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1.1.4 Cyclooxygenase 
COX enzymes, also known as prostaglandin endoperoxide synthases 
(PTGS), are enzymes involved in the rate-limiting step of prostaglandin 
production from AA [42]. They exist in two isoforms: COX-1 (also known 
as PTGS1) and COX-2 (also known as PTGS2). COX-1 is a constitutively-
expressed enzyme found in many tissues. This enzyme is often referred 
as the ‘housekeeping’ form of the COX enzymes and modulates aspects 
of routine functions such as platelet aggregation and gastric acid 
secretion by maintaining basal prostanoid levels [43]. By contrast, COX-2 
is highly induced by a variety of endogenous and external stimuli that 
may include growth factors, tumor promoters, viral or bacterial 
infections as well as a widely range of proinflammatory cytokines [43, 
44]. The gene structures of COX-1 and COX-2 are found at distinct 
genetic loci and differ mainly in size. While COX-1 maps to the long arm 
of chromosome 9 and measures 22 kb, COX-2 maps to the long arm of 
chromosome 1 and measures 8.3 kb [45]. By contrast, both COX 
isoforms share approximately 60% of their protein structure which 
differs in the substitution of a Valine residue in COX-1 for an Isoleucin at 
corresponding position 523 within the active site of COX-2. This change, 
together to the loss of a methyl group, increases the volume of the COX-
2 active site by 25% allowing the accomodation of larger chemical 
structures (Figure 1.2) [46].  
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Figure 1.2: Structure of COX-1 and COX-2 isoforms [46] 
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These differences have been exploited for the development of COX-2 
selective non-steroidal anti-inflammatory drugs (NSAIDs) that are widely 
used in clinical practice for the treatment of chronic inflammatory 
diseases such as osteoarthritis, rheumatoid arthritis and gout showing 
fewer gastrointestinal adverse effects than non-selective NSAIDs [47]. 
Cyclooxygenase enzymes catalyse the oxidation of arachidonic acid to 
form the peroxide intermediate prostaglandin G2 (PGG2) which in turn 
is reduced to prostaglandin H2 (PGH2) (Figure 1.3). The latter acts as a 
substrate for several prostaglandin synthases including PGE2, PGD2, 
PGF2α, PGI2, and TXA2 [48]. Prostaglandins exert their biological effects 
in an autocrine or paracrine fashion by binding to cognate membrane 
bound G-protein-coupled receptors such as DP for PGD2; EP1, EP2, EP3 
and EP4 for PGE2; FP for PGF2α; IP for PGI2; and TP for TXA2. Moreover, 
some prostaglandins and their metabolites bind to intracellular 
peroxisomal proliferator activated receptors (PPARs) inducing their 
transcriptional activity in the nucleus [49]. For example, PGI2 and PGE2 
can bind to PPARβ while, 15-deoxy-Δ12,14-PGJ2 (15dPGJ2), a PGD2 
dehydration product, can bind to PPARγ.  
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Figure 1.3: Eicosanoid synthesis pathway [50] 
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In addition to their synthesis, the extracellular levels and the 
inactivation of prostaglandins is regulated by different transporters and 
enzymes such as the influx prostaglandin transporter PGT; the efflux 
transporter multidrug resistance-associated protein 4 (MRP4); and the 
enzyme hydroxyprostaglandin dehydrogenase 15-(NAD) (HPGD; also 
known as 15-PGDH) that metabolize PGE2 and PGF2α, while other 
prostaglandins are metabolized in a non-enzymatic manner [51]. 
Prostaglandins regulate different biological processes in a wide range of 
tissues under both physiological (mainly ascribed to COX-1 activity) and 
pathological conditions (mainly ascribed to the induction of COX-2). For 
example, PGE2 and PGI2 exert cytoprotective effects in the 
gastrointestinal tract by reducing gastric acid and increasing the release 
of mucous, while in the kidneys these prostaglandins act as vasodilators 
that maintain renal homeostasis [48]. Moreover, prostaglandins control 
the homeostasis of other peripheral tissues such as the cardiovascular 
system, the lungs, reproductive system and the central nervous system.  
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1.1.5 Eicosanoids and cancer  
The concept that inflammation is a critical component of tumour 
progression is not new. In 1863, Rudolph Virchow was the first to 
hypothesize that cancer occurred at sites of chronic inflammation, 
assuming that some classes of irritants, together with the tissue injury 
and consequent inflammation, release factors stimulating cancer cell 
proliferation [52]. In 1957, Burnet and Thomas postulated the existence 
of tumor immunosurveillance: the immunological resistance of the host 
against the development of cancer. Burnet and Thomas proposed that 
lymphocyte populations of the immune system continuously recognized 
and eliminated cancerous and/or precancerous cells arising in the host 
before they could cause harm. In the last years different data 
highlighted the concept that inflammation is a critical component of 
tumour progression and has been reported to be one of the newest 
“hallmarks of cancer” [53]. Different epidemiological data reported that 
about 20% of cancer are linked to chronic inflammation [52]. For 
example, inflammatory bowel diseases are linked to colorectal cancer; 
bronchitis to lung cancer and prostatitis to prostate cancer [54]. Most 
precancerous and cancerous lesions show signs of inflammation 
including innate immune cells, cytokines, and chemokines [55]. For 
example, macrophages in inflammatory bowel disease are 
phenotypically different from normal macrophages and produce 
different cytokines such as IL-1, IL-6, and TNF-α that can promote tumor 
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invasion and metastasis [56]. Among various inflammatory mediators, 
deregulation of prostaglandin mediated signaling as a result of aberrant 
COX expression, has been linked to different types of cancer. In 1994 it 
has been reported that COX-2 is overexpressed in human colorectal 
adenomas and adenocarcinomas and has a key role in inflammatory 
bowel disease and colorectal cancer [57]. Moreover COX-2 has been 
detected in a wide range of cancers including: breast cancer, lung 
cancer, ovarian cancer, colon cancer, colorectal cancer, gliomas, 
prostate cancer, esophageal carcinoma, pancreatic cancer, gastric 
carcinoma, Kaposi’s sarcoma and melanoma [54, 58]. The importance of 
COX-2 in cancer has been demostrated by treatment with aspirin or 
other NSAIDs that inhibit prostaglandin synthesis decreasing the 
incidence of esophageal, colorectal, bladder, lung, and gastric cancer 
[54]. Moreover, COX-2 selective inhibitors (such as celecoxib) showed 
inhibition of adenoma growth in patients at high risk for colorectal 
carcinoma in three different clinical trials. Unfortunately, all three trials 
were aborted because of cardiovascular and gastrointestinal toxicity 
highlighting the importance to develop new classes of anti-
inflammatory agents for cancer therapy [59-61]. Among prostaglandins, 
PGE2 is the most common prostaglandin that is found in various human 
malignancies, including colon, lung, breast, and head and neck cancer, 
and is often associated with a poor prognosis [50]. PGE2 appears to play 
essential roles in tumor cell proliferation, invasion, angiogenesis, and 
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epithelial-mesenchymal transition (EMT), all of which are associated 
with the established or emerging “hallmarks of cancer” [50, 62-64]. 
Another critical mechanism for the potent pro-tumorigenic activity of 
PGE2 is the local suppression of the immune responses [65]. PGE2 
inhibits macrophages, natural killer cells and T cell activation, resulting 
in immunosuppressive and pro-tumorigenic activity [66]. Moreover, 
PGE2, also plays a key role in promoting myeloid derived suppressor 
cells (MDSC) differentiation from bone marrow stem cells that are 
responsible for inhibiting the antitumor immune response; this provides 
a therapeutic approach for anti-cancer therapy [67]. Another strategy to 
inhibit the pro-tumorigenic activity of PGE2 is the overexpression of 15-
PGDH enzyme, which is responsible for the degradation of PGE2. In fact, 
this enzyme results to be down-regulated in human gastric cancer, 
breast cancer, lung cancer, and bladder cancer, suggesting its tumor 
suppressive role [68-71]. Another approach for cancer therapy is the 
inhibition of PGE2 receptors. Mice deficient for EP1, EP2 or EP4 
receptors showed decreased tumorigenesis while administration of 
PGE2 receptor antagonists (such as ONO-8711 which is selective for EP1 
receptor) inhibit tumor growth and can act as chemo-preventive agents 
[72-75].  
In addition to PGE2, there are conflicted data about the role of PGD2 in 
cancer progression. Disruption or overexpression of hematopoietic 
prostaglandin D synthase, which synthesizes PGD2, accelerates or 
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suppresses intestinal tumour growth in mice [76]. By contrast, an 
immunosuppresive effect of PGD2 has been recently reported in human 
acute promyelocytic leukemia (APL) by involving a new class of innate 
immune cells named innate lymphoid cells (ILCs) which in turn activate 
MDSC [77]. 
While COX-2 has been the most extensively studied enzyme in cancer, 
few reports have indicated that LOX enzyme has also an important role 
in tumor progression and survival and is often constitutively expressed 
in various epithelial cancers [78]. However, due to its association with 
the inflammatory response under most physiological conditions as well 
as the overexpression of COX-2 in many tumors, including melanoma, 
the cyclooxygenase pathway will be given the principle focus 
throughout this thesis. 
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1.2 MELANOMA 
1.2.1  Generalities and classification 
Melanocytes are melanin-producing cells located in the basal layer of 
the skin’s epidermis, the uvea, the inner ear, meninges, bones and 
heart. The word “melanin” comes from the ancient Greek melanos, 
meaning 'dark' and is the pigment that provides color and protection 
against ionizing radiations [79]. Cutaneous melanoma is a type of skin 
cancer that arises from abnormal melanocytes proliferation and can 
occur in any anatomic location containing melanocytes. There are four 
different types of skin cancer: basal cell carcinoma (BCC) and squamous 
cell carcinoma (SCC) identified as non-melanoma skin cancers (NMSC) or 
keratinocyte carcinoma; melanoma and other non-epithelial skin 
cancer. Moreover, there are also other uncommon types of skin cancer, 
such as Merkel Cell Carcinoma, Cutaneous T-cell lymphoma and Kaposi's 
sarcoma [80]. BCC and SCC represent approximately 80 % and 16 % of 
all NMSC, respectively. By contrast, melanoma represents less than 5% 
of the skin cancer cases, however, it far the most dangerous as it 
accounts for 80% of all the deaths related to skin cancer [81]. When 
diagnosed in the early stage, melanoma can be easily cured by surgical 
resection. However late metastatic stages are often fatal and, currently 
available or developing treatment strategies, are only able to prolong 
life for a few months, are expensive and may produce severe adverse 
effects [82]. In the past few years melanoma has steadily increased 
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worldwide becoming the 5th neoplasia in America [83]. Its incidence 
varies by geographic location and across different ethnic groups. This 
variation is partly related to decreased photoprotection to UV radiations 
that is well known to induce both cell death and malignant 
transformation of skin cells and are considered the major risk factor for 
melanoma [84]. In 2017 the American Cancer Society and the National 
Cancer Institute estimated 87,110 new cases of patients with invasive 
melanoma and 9,730 deaths only in USA. Melanoma incidence is also 
dependent on gender, infact in the U.S.  is higher in women than in men 
before age 50, but by age 65, rates in men are double those in women, 
and by age 80 they are triple. In addition to UV radiations, genetic 
predisposition and environmental insults contribute to the genesis of 
melanoma. About 10% of melanoma patients report a family history of 
melanoma and are associated with germline mutations in cyclin 
dependent kinase (CDK) gene CDKN2A which is a potent cell cycle 
inhibitor through a direct negative interaction with CDK4. Moreover, 
also xeroderma pigmentosum and MC1R genes have been implicated in 
familial melanomas [85]. These initial observations opened the door to 
additional efforts in understanding the genetics of melanoma, and 
several other mutations have been identified since then. For example, 
the MAPK/ERK and phosphatidylinositol-3 kinase (PI3K/AKT) pathways 
are one of the first most frequently deregulated signaling pathways in 
the great majority of melanomas. In particular, the role of the Ras 
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oncogene family in the melanoma development and their effects on 
downstream signaling were one of the first mutations to be identified, 
then NRAS mutation which is mutated in 15-30% of tumor samples 
leading to serial activation of both the downstream components of the 
RAS effector pathways and the non-MAPK pathways such as PI3K/AKT 
[86]. In 2002 the mutation called ‘Rapidly Accelerated Fibrosarcoma’ 
(RAF) were observed and the V600E variant identified as a frequent 
mutation in cutaneous melanoma [87]. This mutation and the 
consequent constitutive activation of the MAPK pathway has become 
the target of multiple pharmaceutical trials of small molecule inhibitors 
resulting in several new Food and Drug Administration (FDA) approved 
therapies [88]. The other pathway involved in melanoma development 
and progression is PI3K/AKT. In particular, in 12% of melanoma patients 
a lack of the tumour suppressor phosphatase and tensin homolog 
(PTEN) that antagonizes PI3K activity has been detected. Lack of PTEN 
antagonism causes increased phosphorylation of AKT promoting cancer 
cell survival and proliferation [89]. In addition there are also other  
mutations affecting genes that control growth, such as those of Bcl2 
family, production of growth factors and loss of adhesion molecules 
which favor the alteration of intracellular signaling allowing the 
melanocytes to escape from the keratinocyte control [90].  
Pathological features of melanoma can be divided in 5 steps according 
to the Clark model: I) Nevi formation of structurally normal 
CHAPTER 1 
40 
 
melanocytes, II) dysplastic nevi formation, III) radial growth phase (RGP) 
primary melanoma, IV) vertical growth phase (VGP) involving cells that 
have invaded the dermis and cells with metastatic potential and V) 
metastatic melanoma to distant organs (Figure 1.4). The development 
of this illness can be seen as a disruption of normal homeostatic 
mechanisms in the skin. Disruption of the homeostatic control also leads 
to le loss of adhesion molecules such as E-cadherin and the increase of 
N-cadherin that favors the mobility and invasiveness of melanoma cells 
thus the development of metastasis [91].  
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Figure 1.4: Clark and Breslow’s model [92] 
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In addition, the American Joint Committee on Cancer (AJCC) considers 
the Breslow index as the most important prognosis factor in primary 
melanomas. This model measures the melanoma thickness (in 
millimetres) according to the distance between the upper layer of the 
epidermis and the deepest point of tumor penetration (Figure 1.4) [93]. 
According to AJCC the melanoma stages are classified into 4 groups: I 
and II as primary invasive melanomas and III and IV define local regional 
and distant metastasis respectively [94]. However, regular self-skin 
examinations by patients showed to decrease the risk of metastatic 
melanoma at the time of diagnosis expecially when coupled with regular 
visits to a dermatologist [95]. The A-B-C-D-E guide, devised by the 
american cancer society, highlights several clinical features of 
melanoma, including asymmetry, border, color, diameter and evolution 
(Figure 1.5).  
A = asymmetry, when the two halves of the lesion do not match. 
B = border, when the edge are irregular or uneven. 
C = color, when the lesion doesn’t have an uniform color but rather a 
combination of black, brown, blue, or even white.  
D = diameter, when the lesion is larger than 6 mm. 
E = evolution, when the lesion changes in size, color or shape.  
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Figure 1.5: The A-B-C-D-E guide 
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1.2.2     Immune response in melanoma 
The concept of immune response in tumors was propose for the fist 
time by Paul Ehrlich in 1907 and later expanded when Coley obtained 
tumor reduction after injection of bacteria into tumors [96]. This kind of 
work revealed the importance of studying the relationship of host 
immune response to tumors and patients’ survival. The work that 
followed showed that injection of melanoma cell lysates resulted in 
2/26 patients with total remission and 5/26 with partial tumor 
regression. Furthermore, it was observed that patients injected with 
irradiated melanoma cells increased the index of lymphotoxicity. In all 
cases histology from regressing tumors showed high lymphocyte 
infiltration [96]. In fact, the importance of lymphocytes in tumors has 
been long recognized but their possible role in melanoma prognosis has 
been debated and only recognized in the past 40 years. Some groups 
showed increased survival and improved prognosis in patients with mild 
and high lymphocyte infiltration and finally established 3 categories: 
Brisk (dense infiltrate), No brisk (mild infiltrate) and absent [97, 98].On 
the contrary, other groups failed to show a positive correlation between 
tumor infiltrating lymphocytes (TILs) and prognosis or patients’ survival 
[99-101]. Discrepancies in those results could be explained by the 
extreme diversity of the patients included in the studies and the fact 
that no phenotypic characterization of those TILs was done [102], in fact 
studies were such characterization was done, showed that CD8+ T cell 
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infiltration improve prognosis [103]. More answers to this might be 
found in the understanding of the role of inflammatory cytokines in 
lymphocyte functions, and the immunosuppressive aspects of other 
cells in the tumor microenvironment [96]. Human tumors bear antigens 
that can be recognized by autologous T lymphocytes. Some of these 
antigens appear to be tumor specific (neo-antigens), whereas others are 
also present on normal tissues such as overexpressed antigens or viral-
derived antigens. Specifically in melanoma, several tumor specific 
antigens have been described making easier the assessment of the anti-
tumor immune response [104, 105]. After identification of melanoma 
antigens several groups reported evidence about the existence of a 
spontaneous anti-tumoral T cell response in patients. For example it has 
been reported that tumor-specific CD8+  T lymphocytes from melanoma 
patients have a memory effector phenotype (TEM) (CCR7+, CD4+45RO+) 
while healthy donors bear naive tumor-specific T lymphocytes (CCR7+, 
CD4+45RA+) [106, 107]. In addition TILs of melanoma patients were 
shown to contain not only CD8+ T cells but also CD4+ T cells recognizing 
melanocyte differentiation antigens and cancer testis antigens [108]. In 
conclusion, spontaneous T cell response correlates with a better 
prognosis, even though the correlation may be obscured in some 
circumstances by the fact that most metastatic melanoma patients are 
progressing despite having mounted a quantitatively significant T cell 
response against their tumor [109]. T cell unresponsiveness does not 
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seem to be due to their failure to reach the tumor sites but the anti-
tumoral T cell response must become ineffective at one point, either 
because the tumor cells have become insensitive to the effector cells or 
because the effector cells themselves have become unable to be 
stimulated by the antigen or to exert their function, a state also refered 
as “exhaustion”. This exhausted state could result from inhibitory 
processes elicited by tumor cells that were selected by the immune 
response (immunoediting), the loss of antigen or MHC molecules [110], 
the expression of immunosuppressive factors such as Indoleamine 2,3-
dioxygenase (IDO) and prostaglandins [111, 112], the secretion of 
immunosuppressive cytokines such as IL-10 and TGFβ [113], arginase 
expression [114, 115], TREG infiltration [116] or the expression of PDL-1 
molecule at the surface of tumor cells among others [117].  
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1.2.3 Treatment and immunotherapy in melanoma 
In the last 30 years many drugs and combination of drugs have been 
introduced in melanoma therapy to improve patient survival for longer 
time. Cytotoxic chemotherapy was the main approach for metastatic 
melanoma while radiation therapy is used in 1–6% of patients with 
melanoma in the US in the setting of inoperable disease [118]. Common 
antineoplastic agents currently being used include dacarbazine and 
temozolomide that, in monotherapy, showed low overall response rates 
(approximately 10%-15%). In the past decades, the increasing 
knowledge in cellular immunology and tumor led to the development of 
immunotherapy approaches. One of the first approaches was the 
discovery of the T cell growth factor IL-2 that was the first agent used to 
modulate the immune system for the treatment of patients with 
metastatic melanoma [105]. It was approved by the FDA in 1998 but its 
response rate was low (approximately 16%) and showed marked 
secondary effects [119]. In fact, before 2010 none of the systemic 
therapies approved for metastatic melanoma treatment showed to 
increase patients’ survival, and only little improvement was observed by 
using TNF-α as co-adjuvant. Currently, treatment with BRAF inhibitors, 
which are included in the “target therapy" drugs, have been used to 
treat melanoma patients bearing this mutation that constitutive 
activates MAPK pathway. However, BRAF inhibitor Vemurafenib, 
approved by the FDA in 2011, can only be used in approximately 50% of 
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melanoma patients where the V600E mutation is present [120]. There 
are also other BRAF inhibitors approved such as Dabrafenib and 
Trametinib but unfortunately, an important percentage of the patients 
acquire drug resistance loosing response to the therapy and tumor 
progression approximately after 6-8 months [121]. After the BRAF 
inhibitors’ development, the interest about therapy continued to grow 
and the latest clinical advances in melanoma treatment have targeted 
immune response by blocking inhibitory checkpoint molecules. In 
particular, the two best characterized are CTLA-4 and PD-1 for which 
monoclonal antibodies have been developed and already approved by 
the FDA. For example, Tremelimumab was the first anti-CTLA-4 agent to 
be investigated in patients with metastatic melanoma. Although in 
phase I/II clinical trials, it showed antitumor activity in patients with 
stage III/IV melanoma, a phase III study failed because tremelimumab 
didn’t demonstrate any benefit over chemotherapy [122]. More 
successes has had Ipillimumab (Yervoy®) approved by FDA in 2011. 
Ipilimumab blocks the CTLA-4 molecule favoring the activation state of T 
lymphocytes. CTLA-4 or CD152 works as an inhibitory receptor for the 
co-stimulatory signal delivered by the interaction with B7 expressed on 
the surface of antigen presenting cells (APC) [123] and has been also 
reported to be capable of depleting regulatory T cells (T-reg) [124]. In 
patients Ipillimumab showed an overall response of 11% [125] and, in 
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combination with dacarbazine, it improved patients’ survival for 11,2 
months with 24% reduction of patients’ disease relapse [126]. 
Another inhibitory checkpoint is the PD-1/PDL-1 pathway. 
Physiologically, PD-1/PDL-1 interaction limits T cell activity in the setting 
of an inflammatory response. PD-1 is expressed in activated T, B and NK 
cells, whereas PDL-1 or PDL-2 are expressed on immune cells as well as 
tumor cells. PD-1 has been shown to be express on TILs while circulating 
melanoma antigen specific T cells and melanoma tumors express PD-L1 
which induce T cell anergy and immunosuppression [105]. Nivolumab 
(Opdivo®) is directed against PD-1 and showed 28% of clinical response 
with a dosage of 3 mg/kg bodyweight and with a low rate of toxicity, 
infact the most common side effects are diarrhea, rush, and pruritus 
[127]. Pembrolizumab (formerly known as lambrolizumab) is a second 
anti-PD-1 agent approved by FDA on September 2014. It showed 25% of 
clinical response at low doses and 52% at high doses and 77% of the 
patients showed tumor regression [128]. 
Immunotherapy, based on adoptive cell transfer (ACT) of ex-vivo 
activated and expanded TILs, has shown promising clinical results in 
patients with metastatic melanoma. TIL therapy after lymphodepletion 
showed response rates of around 50% and significant survival benefit in 
refractory melanoma patients [129]. However TIL-based ACT is an 
individualized treatment that requires specialized laboratories and is 
more complex to perform than conventional therapies. Today, properly 
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designed clinical trials are required to formally demonstrate the 
advantages of this kind of therapies over the classic treatment 
modalities. In addition, identifying predictors of TIL efficacy and 
detection of TIL subsets with specific reactivity against tumors is 
necessary to improve the clinical responses and patients survival [130]. 
Other types of immunotherapies are cancer vaccines that have been 
also tested in the past decade and, in the last years, their development 
has been evolved in a significant manner in antigenic composition, 
delivery methods, adjuvants, treatment frequency and administration 
techniques [129]. Nonetheless, this approach has not been very 
successful in terms of objective response and patients survival. Current 
immunotherapy approaches for melanoma show encouraging results 
and the inefficacy of some of these therapies could be explain by 
different reasons such as the type of adjuvants used during the 
vaccination process [131], expression of exhaustion markers, loss of 
functionality, limited access to tumor site and the immunosuppressive 
tumor microenvironment [132]. 
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1.2.4   The role of inflammation in melanoma and NMSC 
As previously reported, inflammation is linked with several stages of 
tumor development, including initiation, promotion, invasion, and 
metastasis [133]. NF-κB protein is the main player in inflammation and, 
together with other molecules including cytokines, chemokines, ROS, 
oncogenes, inflammatory enzymes (COX-2 and LOX), anti-apoptotic 
proteins, transcription factors (STAT3, AP-1, CREB, NRF2) regulate tumor 
cell proliferation, transformation, and survival [134]. Cell lines from SCC 
showed high expression of activated NF-κB while, other cancer cells, 
including melanoma cells, showed higher expression of STAT-3 which in 
turn up-regulates anti-apoptotic proteins such as Bcl-2 and controls the 
expression of cyclins and the proto-oncogene c-Myc [135]. 
Different cytokines also control the inflammatory milieu promoting 
tumor progression. For example, IL-6 showed a direct effect on cancer 
cell growth and survival in melanoma [136]. The expression of 
inflammatory cytokines is induced by different pathways, including 
MAPK and in particular RAS, which is mutated in approximately 25 % of 
all malignancies, and has also been reported to be linked with tumor 
progression locus 2 (Tpl2) which in turn favors ERK phosphorylation and 
is associated with resistance to the Raf kinase inhibitor PLX4720 [137].   
IL-6 is induced by UV radiation in keratinocytes [138] and promotes 
angiogenesis in human BCC line by inducing b-fibroblast growth factor 
(bFGF) via PI3-kinase/Akt pathway. Moreover, silencing of COX-2 by 
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siRNA reduced angiogenic activity of IL-6, suggesting that COX-2 also 
plays a role in IL-6-induced angiogenesis [139]. 
COX-2 has also a key role in keratinocyte differentiation and, chronic 
exposure to UV radiations, induces its over-expression that, together 
with the accumulation of DNA damage and mutations, causes malignant 
changes in epidermal keratinocytes and skin cancers [140]. Moreover, 
COX-2 up-regulation is also induced by different molecules such as 
TGFβ1 affecting the invasion and the metastatic spread of melanoma 
cells [141]. In addition, also IL-1α cytokine has been reported to induce 
the expression of COX-2 [142]. In fact, over-expression of the antagonist 
of IL-1α in mouse skin carcinoma cell line results in down-regulation of 
COX-2 expression and slower in vitro and in vivo growth [140]. The 
important role of COX-2 in tumor promotion has been also 
demonstrated in vivo by using transgenic mouse model, wherein COX-2 
over-expressing transgenic mice are highly susceptible to develop 
spontaneous skin tumor [143], while COX-2 knockout mice are less 
inclined to induce tumor development [144]. 
Increase in COX-2 causes a consequent increase in the level of PGs, 
which are up-regulated in various premalignant and malignant tissues 
and are functionally related to mouse skin tumor promotion [145]. 
PGE2, which is engaged in normal skin homeostasis, has been shown to 
be a key player mediating the involvement of the COX-2 pathway to 
cancer development. Elevated levels of PGE2 were observed in 
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melanoma and have been correlated to cancer cell invasion and 
migration [146]. Several studies have shown increased expression of 
EP1 receptor in murine skin tumor cells and that this receptor is decisive 
for the mitogenic effects of PGE2 on these cells in vitro [147]. Moreover, 
even topical application of PGD2 dehydration product, 15dPGJ2, has 
been shown to potentiate mouse skin tumorigenesis [148]. 
Taken together, the relation between inflammation and tumor 
development and progression has been sustained supported by an 
extensive number of clinical studies in particular regarding the 
treatment with both COX-2 selective or not selective NSAIDs. However, 
these studies do not consent any acumen in the cellular and molecular 
mechanisms that are at the basis of the relation between tumor 
progression and inflammation in melanoma and NMSC.  
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CHAPTER 2: AIM 
Inflammation has emerged as a major factor promoting cancer 
development. In the current literature there is an increasing interest for 
the role played by COX- 1 and COX-2, the key rate-limiting enzymes 
involved in regulation of PGE2 synthesis. In particular, the COX-2 
isoform has been shown to be constitutively expressed in various 
cancers, predominantly by stromal cells [50]. In melanoma COX-2 
expression has been detected in human specimens and murine models 
[149, 150] and has been proposed to be correlated with the 
development and progression of disease [151-153]. More recently this 
concept has been reinforced by the finding that increased levels of PGE2 
are associated with enhanced cancer cell survival, growth, invasion, 
angiogenesis and immunesuppression [50]. In fact it is recognized that 
the consumption of certain anti-inflammatory drugs, including aspirin, 
can significantly reduce cancer risk, suggesting that common NSAID and 
more specific COX-2 inhibitors can be used in cancer prevention [154]. 
In addition, recent evidences demonstrated that microRNAs (miRNAs), 
that play a critical role in the post-transcriptional regulation of gene 
expression and regulate many aspects of tumor progression [155, 156] 
have a huge impact as important cancer prevention genes. In particular, 
several miRNAs have been demonstrated to be important direct 
regulators of COX-2 gene expression in cancer or non cancer cells [157]. 
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Starting from this evidence, the aim of my PhD project was to 
investigate the role of the cyclooxygenase pathway in human melanoma 
development and progression.  
To address this issue we: 
1) Evaluated the correlation between COX-2 expression and disease 
progression in human melanoma.  
 
2) Evaluated the role played by COX inhibitors in preventing melanoma 
progression. 
 
3)  Evaluated the effect of COX-2 deletion in the tumor cells rather than 
in the tumor microenvironment by using CRISPR/Cas9 technology 
and investigated the role of miR-143-3p in human malignant 
melanoma.  
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CHAPTER 3: MATERIALS AND METHODS 
3.1 IN VITRO EXPERIMENTS 
3.1.1 Patients and specimens 
The retrospective study samples consisted of 45 metastatic lymph node 
samples obtained from melanoma patients who underwent surgical 
resection from September 2001 to January 2009 in Istituto Nazionale 
per lo Studio e la Cura dei Tumori “Fondazione G. Pascale”, Naples 
(Italy) and were enrolled in a specific clinical protocol where all the 45 
patients were diagnosed with lymph node metastases after the first 
surgery (“in progress disease”). PFS was selected as primary outcome. 
The melanomas were divided according to the AJCC TNM classification 
for melanoma staging into four groups pT1 (n = 6 melanomas), pT2 (n = 
12 melanomas), pT3 (n = 1 5 melanomas) and pT4 (n = 12 melanomas). 
The number of patients in the different sub-groups were: for levels of 
COX-2 expression <=9% (n=23); for levels of COX- 2 expression >10% 
(n=22).  
3.1.2 Tissue micro-array 
Tissue micro-array (TMA) was built using the two representative areas 
from each single case. All tumours areas were selected by two 
experienced pathologists. Finally, two tissue cylinders (diameter 1 mm) 
were punched from morphologically representative tissue areas of each 
donor tissue block and brought into one recipient paraffin block using a 
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semi-automated tissue arrayer (Galileo TMA CK3500, Integrated System 
Engineering srl, Milan, Italy). 
3.1.3 Immunohistochemistry analysis 
Immunohistochemical staining was carried out on TMA 4-μm section to 
evaluate the expression of COX-2 marker. Briefly, paraffin slides were 
deparaffinized in xylene and then rehydrated through alcohol gradient. 
Antigen retrieval was performed by decloaking chamber™ (Biocr 
Medical) in 0.01 M citrate buffer for 10 min. After peroxidase and 
protein block (BSA 5% in 1X PBS), the slides were incubated with 
primary antibody to human COX-2 (D5H5 XP® Cell Signaling). Antigen 
expression was evaluated independently and blindly by two experienced 
pathologists using light microscopy. The percentage of cancer cells with 
cytoplasmic staining was determined by counting the number of 
positive cells as a fraction of the total number of cancer cells in tissue 
cores at ×400 magnification as follow:  
 
The median value of positive expression (9%) was used as the cut-off 
point for statistical analyses to distinguish tumours with negative or low 
COX-2 expression (≤9%; COX-2low) from tumours with high COX-2 
expression (≥10%; COX-2high). 
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3.1.4 Cell culture and reagents 
Normal Human Epidermal Melanocytes (NHEM) were purchased from 
Lonza (Walkersville, MD, USA) and were grown in Melanocyte growth 
medium 2 (Lonza). The melanoma cell lines B16/F10, Sk-Mel-5 and Sk-
Mel-28 were purchased from IRCCS AOU San Martino – IST (Genova, 
Italy), A375 from Sigma-Aldrich (Milan, Italy) and were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal 
bovine serum, 2 mmol/L L-glutamine, 100 μmol/L non essential amino 
acids, penicillin (100 U/mL), streptomycin (100 μg/mL) and 1 mmol/L 
sodium pyruvate (all from Sigma-Aldrich, Milan, Italy). WM35, WM983A 
and WM983B were from Rockland (Limerick, Ireland) and were cultured 
in Tumor Specialized Media (1:5 Leibovitz’s – MCDB153), containing 2% 
inactivated FBS and 1,68 mM CaCl2. The cell line PES43 was isolated 
from a lung metastases of a patient from the National Cancer Institute, 
G. Pascale Foundation and cultured in Iscove’s modified Dulbecco’s 
medium (Cambrex Bioscience, Verviers, Belgium) supplemented with 
heat-inactivated 10% FBS, penicillin, and streptomycin (100 units/mL 
each). Cells were grown at 37°C in a humidified incubator under 5% CO2. 
All cell lines used in this study were characterized by the cell bank were 
they were purchased. Celecoxib (Selleck Chemicals, Munich, Germany) 
and naproxen (Sigma-Aldrich, USA) were solubilized in H2O. ATB-346 
and 4-hydroxy-thiobenzamide (TBZ) were synthesized by Antibe 
Therapeutics Inc. (Toronto, ON, Canada) and were solubilized in DMSO. 
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3.1.5 RNA purification and quantitative real-time PCR (qPCR) 
Total RNA was isolated from cells by use of the TRI-Reagent (Sigma-
Aldrich, Milan, Italy), according to the manufacturer’s instructions, 
followed by spectrophotometric quantization. Final preparation of RNA 
was considered DNA- and protein-free if the ratio between readings at 
260/280 nm was ≥ 1.7. Isolated mRNA was reverse-transcribed by use of 
iScript Reverse Transcription Supermix for RTqPCR (Bio-Rad, Milan, 
Italy). The quantitative real-time PCR was carried out in CFX384 real-
time PCR detection system (Bio-Rad, Milan, Italy) with specific primers 
(hCOX-1 5′-AAGGTGGCATTGACAAACTCC-3′, 5′-CG 
CCAGTGATCCCTGTTGTT-3′; hCOX-2 5′-TAAGTGC GATTGTACCCGGAC-3′, 
5′-TTTGTAGCCATAGTCAGCATTGT-3′; mCOX-2 5′-
TACCCTCCTCACATCCCTGA -3′, 5′-CCTGCTTGAGTATGTCGCAC-3′) by the 
use of SYBR Green master mix kit (Bio- Rad, Milan, Italy). Samples were 
amplified simultaneously in triplicate in one-assay run with a non-
template control blank for each primer pair to control for contamination 
or primer dimer formation, and the ct value for each experimental 
group was determined. The housekeeping gene (ribosomal protein S16) 
was used as an internal control to normalize the ct values, using the 2-ΔCt 
formula. 
For the miR-143-3p study, total RNA was isolated from 20-μm sections 
from formalin-fixed, paraffin-embedded tissue blocks according to the 
protocol of miRNeasy FFPE Kit (Qiagen, Valencia, CA).  Total RNA was 
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reversely transcribed using miScript II RT Kit (Qiagen, Valencia, CA). 
Quantitative real-time PCR was carried out in CFX384, as described 
above, by the use of miScript SYBR Green PCR Kit (Qiagen). The U6 
expression level was used as an internal control miRNAs.  
3.1.6 Proliferation assay 
Cell proliferation was measured by the 3-[4,5-dimethyltiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT). Briefly, the human melanoma cells 
and the NHEM cells were seeded on 96-well plates (2 x 103 cells/well) 
and treated with celecoxib (10-100 μM) or naproxen (10-100 μM) for 
24-48-72 h before adding 25 μL of MTT (Sigma, Milan, Italy) (5 mg/mL in 
saline). Cells were thus incubated for an additional 3 h at 37°C. After this 
time interval, cells were lysed, and dark blue crystals were solubilized 
with a solution containing 50% N,N-dimethyl formamide and 20% 
sodium dodecylsulfate with an adjusted pH of 4.5. The optical density of 
each well was measured with a microplate spectrophotometer 
(TitertekMultiskan MCC/340), equipped with a 620 nm filter. 
For the pharmacological modulation study with ATB-346, cells were 
treated with ATB-346 (10–100 μM), TBZ (10–100 μM) or naproxen (10–
100 μM) for 24–48–72 h, then we followed the same method described 
above.  
For the CRISPR/Cas9 study, B16/F10, B16/PTGS2Δ and B16/Scramble 
cells were seeded on 96-well plates (2 x 103 cells/well) and then we 
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evaluated the growth rate at 24-48 and 72 h by following the same 
method described above. 
For the miR-143-3p study, the human melanoma cells A375 were 
seeded on 96-well plates (3×103 cells/well) and the next day transfected 
with miR-143-3p mimics, scramble or pCMV6-AC-PTGS2. MTT was 
added to the cells at 24-48-72 h post transfection, then we followed the 
same method described above.  
3.1.7 COX-2 small interfering RNA transfection of SK-Mel-5 
For the silencing experiments SK-Mel-5 were seeded onto 96-well plates 
(2 x 103 cell/well) and transfected the next day, according to the 
manufacturer’s instruction, with PTGS2 Trilencer-27 Human siRNA 
(OriGene, Rockville, MD, USA) (rCrCrArArUrUrGrUrC 
rArUrArCrGrArCrUrUrGrCrArGrUGA;rGrGrCrUrArArUrArCrUrGrArUrArGr
GrArGrArGrArCrUAT;rGrCrArGrCrUrUrCrCrUrGrArUrUrCrArArArUrGrArG
rATT). The final concentration of the siRNA pool was 10 nM. Forty-eight 
hours after transfection, cell proliferation was evaluated by MTT assay 
(see Proliferation assays). The knockdown of COX-2 expression in cells 
after transfection was confirmed using western blot analysis. The 
Universal scrambled negative control siRNA duplex was used as negative 
control. 
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3.1.8 Preparation of cell lysates and western blot analysis 
Melanoma cells were harvested, washed with cold phosphate-buffered 
saline and lysed with ice-cold lysis buffer supplemented with protease 
inhibitors. Equal amounts of proteins were resolved on 10% Tris–Glycine 
gels and transferred onto a nitrocellulose membrane. After blocking the 
nonspecific binding sites, the membrane was incubated with the 
primary antibody (COX-2; cod: 12282; batch 2; diluited 1:1000, Cell 
signaling, MA, USA) at 4°C overnight. The membrane was then 
incubated with the appropriate peroxidase-conjugated secondary 
antibody and the immunoreactive bands were visualized using the 
enhanced chemiluminescence reagents. To verify equal protein loading, 
the membrane was stripped and reprobed with anti-b actin antibody.  
For the pharmacological modulation study with ATB-346, A375 cells 
were treated with ATB-346, TBZ and naproxen, 100 µM for 6 and 24 h. 
Whole-cell or nuclear extracts were prepared as described above, then 
the filters were incubated with the following primary antibodies: IĸBα 
(sc-1643 Cruz Biotech-nology, Santa Cruz, CA; diluted 1:200); Bcl-2 
(2876, Cell Signaling,USA; diluited 1:1000), caspase 3 (9662, Cell 
Signaling, USA; diluited1:1000), PARP (9542, Cell Signaling, USA; diluited 
1:1000), Akt (9272, Cell Signaling, USA; diluited 1:1000), Phospho-Akt 
(Ser473)XP (4060, Cell Signaling, USA; diluited1:2000), XIAP (R&D Sys-
tem, Minneapolis; 1 µg/mL); NF-ĸB p65 (F-6): (sc-8008 Santa 
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CruzBiotechnology, Santa Cruz, CA; diluted 1:200); β-actin (Santa 
CruzBiotechnology. 
For the CRISPR/Cas9 study, B16/F10, B16/PTGS2Δ and B16/Scramble 
whole-cell extracts were prepared as described above, then the filters 
were incubated with the primary antibody (COX-2; cod: 12282; batch 2; 
diluited 1:1000, Cell signaling, MA, USA) at 4°C overnight. To verify 
equal protein loading, the membrane was stripped and reprobed with 
anti-GAPDH antibody. 
For the miR-143-3p study, whole-cell extracts were prepared as 
described above, then the filters were incubated with the primary 
antibody (COX-2; cod: 12282; batch 2; diluited 1:1000, Cell signaling, 
MA, USA). To verify equal protein loading, the membrane was stripped 
and reprobed with anti-GAPDH antibody. 
3.1.9 Cell invasion assay 
The assay was performed using chambers with polycarbonate filters 
with 8-μm nominal pore size (Millipore, USA) coated on the upper side 
with Matrigel (Becton Dickinson Labware, USA). The chambers were 
placed into a 24-well plate. Two groups of melanoma cells (2.5x105/mL) 
were harvested and placed in the upper chamber in serum-free DMEM: 
SK-Mel-5 CTL and siRNA COX-2 transfected SKMel- 5. The bottom 
chamber contained DMEM with 10% FBS. After the incubation period 
(16h), the filter was removed, and non-invaded cells on the upper side 
of the filter were detached with the use of a cotton swab. Filters were 
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fixed with 4% formaldehyde for 15 min, and cells located in the lower 
filter were stained with 0.1% crystal violet for 20 min and then washed 
with PBS. The filters were examined microscopically and cellular 
invasion was determined by counting the number of stained cells on 
each filter in at least 4–5 randomly selected fields. Resultant data are 
presented as a mean of invaded cells ± SD/microscopic field of three 
independent experiments. 
For the CRISPR/Cas9 study, B16/F10, B16/PTGS2Δ and B16/Scramble 
(2.5 × 105/mL) were plated in the upper chamber in serum-free DMEM, 
then we followed the same method described above. 
For the miR-143-3p study, A375 cells (2.5×105) transfected with miR-
143- 
3p mimics or scramble, were plated to the upper chamber in serum-free 
DMEM, then we followed the same method described above. 
3.1.10 Annexin V-FITC/PI Flow Cytometry 
Annexin V and Propidium Iodide were used for the pharmacological 
modulation study with ATB-346. A375 cells were seeded in 35 mm 
culture dishes and allowed to attach overnight. The cells were treated 
with ATB-346 (100 µM), TBZ (100 µM) or naproxen (100 µM) for 24–48, 
collected and washed twice with PBS. Samples were then taken to 
determine baseline and drug-induced apoptosis by Annexin V-
FITC/Propidium Iodide(PI) (Beckman Coulter; Brea, CA) double staining 
or PI staining and flow cytometry analysis using a FACS Canto II 6-colour 
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flow cytometer (Becton Dickinson Biosciences, San Jose, CA). To detect 
early and late apoptosis, both adherent and floating cells were 
harvested together and resuspended in annexin V binding buffer (10 
mM HEPES/NaOH pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) at a 
concentration of 106 cells/mL. Subsequently, 5 µL of FITC-conjugated 
Annexin V and 5 µL of PI were added to 100 µL of the cell suspension 
(105 cells). The cells were incubated for 15 min at room temperature in 
the dark. Finally, 400 µL of annexin V binding buffer was added to each 
tube. A minimum of 50,000 events for each sample were collected and 
data were analyzed using FacsDivasoftware (Becton Dickinson 
Biosciences). 
3.1.11 Elisa 
CXCL1/KC plasma concentrations were evaluated for both 
pharmacological modulation study with ATB-346 and CRISPR/Cas9 study 
by using ELISA kit according to the manufacturer’s instruction (DuoSet 
ELISA, R&Dsystems, Minneapolis, MN, USA). 
3.1.12 Knockdown of PTGS2 with CRISPR-Cas9 
A CRISPR knock-down kit against mouse PTGS2 was purchased from 
OriGene (USA, Cat# KN314183). Transfections were performed as 
recommended by the manufacturer. Briefly, 3 × 105 B16/F10 cells were 
seeded into 6 well plates and maintained for 24 hours. TransIT-X2 
(Mirus, Cat# MIR6003) was used at a final concentration of 2.4% 
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together with a total of 2 μg plasmid (1 μg gRNA or Scrambled control 
with 1 μg donor) per well. TransIT-DNA complexes were made up in 
serum-free growth medium. Cells were maintained for 48 hours before 
cells were returned to growth medium. Transfected cells were sub-
cultured 7 times before puromycin selection (1 μg/ml, SantaCruz, 
Cat#sc-108071). Selected cells (puromycin resistant) were screened for 
expression of PTGS2 by quantitative real-time PCR (qPCR) and Western 
blot analysis. 
3.1.13 Wound healing assay 
Wound healing assay was used for the CRISPR/Cas9 study. B16/F10, 
B16/PTGS2Δ and B16/Scramble were seeded in 12-well plates (2×105 
cells/well). Once the cells reached 90% confluency, a wound area was 
carefully created by scraping the cell monolayer with a sterile 200 μl 
pipette tip. After being washed three times with PBS, scratches 
including the flanking front lines of cells, were photographed (20-fold 
magnification). Subsequently, the cells were incubated at 37°C in 5% 
CO2. The width of the wound area was monitored with an inverted 
microscope at various time points. Wound closing was compared 
between B16/PTGS2Δ cells and B16/Scramble cells after measuring the 
wound area and evaluated using Image J software (LASV3.8, Germany). 
Differences between the data points were determined by Student’s t 
test where p < 0.05 was considered significant. Experiments were 
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performed independently two times, evaluating 4 – 8 scratches in each 
experiment. 
3.1.14 Clonogenic assay 
For the CRISPR/Cas9 study, B16/F10, B16/PTGS2Δ and B16/Scramble 
(1x103 cells/well) were seeded in 6-well plates. The medium was 
changed every 2 days. Cells cultured for 14 days were washed twice 
with 1X PBS, fixed by 4% paraformaldehyde, and stained with 0.5% 
crystal violet and colonies containing more than 50 cells (established by 
microscopy) were counted manually. Images of the colonies were 
obtained using a digital camera. The experiments were done in 
duplicate at least three times. 
For the miR-143-3p study, miR-143-3p mimics or control (scramble) – 
transfected A375 cells were seeded onto a 6-well plate (1×103 cells/well) 
and allowed to grow for two weeks, then we followed the same method 
described above. 
3.1.15 miR-143-3p mimics transfection 
miR-143-3p mimics and negative control (scramble) were purchased 
from Qiagen, (Valencia, CA), pCMV6-AC-PTGS2 was purchased from 
Origene Technologies Inc. (Rockville, MD, USA). The human melanoma 
cells A375 were transfected with miR-143-3p mimics (25 nM), scramble 
or pCMV6-AC-PTGS2 using TransIT Transfection Reagent (Mirus Bio LLC, 
Madison, WI USA) according to the manufacturer’s instruction. 
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3.1.16 Apoptosis assay 
Apoptosis assay was used for the miR-143-3p study. Human melanoma 
cells A375 were seeded onto 96-well plates (3×103 cells/well) and 
transfected with miR-143-3p mimics (25 nM) and control (scramble) 
sequences. Apoptosis assay was performed 48 h post transfection using 
the ApoTox‐Glo™ Triplex Assay according to the manufacturer’s 
instructions (Promega, Madison, WI). 
3.1.17 Cell migration assay 
Migration assay was used for the miR-143-3p study. Cell migration was 
performed by use of a transwell chamber (8 μm, 24-well insert; Corning, 
Lowell, MA, USA). A375 cells (2.5×105) transfected with miR-143- 3p 
mimics or scramble, in serum-free medium were added to the upper 
chamber and medium containing 10% FBS was added to the lower 
chamber.  Cells were then incubated for 18 h. Finally, cells that migrated 
into the lower chambers were fixed with methanol, stained with crystal 
violet, and counted in six random fields using ImageJ (MD, USA). 
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3.1.18 miRNA target prediction 
The prediction of putative miRNA target sites on COX-2 mRNA was 
performed using three commonly used free softwares: TargetScan 
(http://www.targetscan.org), miRanda (http://www.microrna.org/) and 
PicTar (http://pictar.mdc-berlin.de/). 
3.1.19 Luciferase reporter activity assay 
The pMirTarget-PTGS2-3’-UTR luciferase construct was obtained from 
Origene Technologies Inc. (Rockville, MD, USA). The A375 cells were 
transfected with 100 ng of pMirTarget-PTGS2-3’-UTR and miR-143-3p 
mimics (25 nM) or scramble using TransIT Transfection Reagent (Mirus 
Bio LLC, Madison, WI) according to the manufacturer’s instruction. After 
48 h, the cells were harvested and assayed using the Dual-Glo Luciferase 
Assay (Promega, Madison, WI). 
3.1.20 Prostaglandin E2 assay 
PGE2 concentrations was evaluated in cell culture supernatants 
obtained from miR-143-3p mimics or scramble transfected A375 cells. 
Prostaglandin E2 EIA kit (Cayman Chemicals, Ann Arbor, MI)) was used 
according to the manufacturer’s instruction. 
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3.2 IN VIVO EXPERIMENTS 
3.2.1 Animals 
The experimental procedures, according to Italian (DL 26/2014) and 
European (n. 63/2010/UE) regulations on the protection of animals used 
for experimental and other scientific purposes, were approved by the 
Italian Ministry. All studies involving animals are reported in accordance 
with the ARRIVE guidelines for reporting experiments involving animals 
[158]. Mice were observed daily and humanely euthanized by CO2 
inhalation if a solitary subcutaneous tumor exceeded 1.5 cm in diameter 
or mice showed signs referable to metastatic cancer. All efforts were 
made to minimize suffering. Male or female C57BL/6 mice (18−20 g) 
were purchased from Charles River Laboratories, Inc. Male COX-2–/– 
mice, kindly supplied by Dr Jane A. Mitchell, back-crossed for >7 
generations onto a C57Bl/6J background were used at 10 to 12 weeks of 
age. Animals were genotyped before use [159]. Mice were housed at 
the Animal Research Facility of the Department of Pharmacy of the 
University of Naples Federico II. 
3.2.2 Induction of subcutaneous melanoma 
Mice were subcutaneously (s.c.) injected in the right flank with B16-F10 
murine melanoma cells (1×105/0.1ml). Tumour size was measured using 
a digital caliper, and tumour volume was calculated using the following 
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equation: tumour volume = π/6(D1xD2xD3) where D1=length; 
D2=width; D3= height and expressed as cm3. 
For the pharmacological modulation study with ATB-346, groups of mice 
(n = 8 each) were treated orally, twice daily beginning on day 1, with 
equimolar doses (43 µmol/kg) of ATB-346, naproxen or TBZ. The control 
group was treated with an equal volume of vehicle. All tested drugs 
were suspended in dimethylsulfoxide/1% carboxymethylcellulose (5:95 
ratio) then we evaluated tumor volume as described above. 
For the CRISPR/Cas9 study, mice were s.c. injected with B16/F10, 
B16/PTGS2Δ and B16/Scramble cells (1 × 105/0.1 ml) then we evaluated 
tumor volume as described above. 
3.2.3 Statistical analysis 
To analyze the correlation between COX-2 expression and BRAF or NRAS 
mutation the Mann-Whitney non-parametric test was used. Progression 
free survival (PFS) curve was calculated with the Kaplan- Meier method 
and analyzed with the log-rank test. P values less than 0.05 were 
considered to be statistically significant. Data from both in vitro and in 
vivo experiments are reported as the mean ± SEM. Data were analyzed 
using GraphPad Prism software (GraphPad). Significance was 
determined using a Student’s two-tailed t test. Results were considered 
significant at P value less than 0.05 and are labeled with a single 
asterisk. In addition, P values less than 0.01 and 0.001 are designated 
with double and triple asterisks, respectively.
 73 
 
CHAPTER 4: RESULTS 
4.1 DIFFERENTIAL EXPRESSION OF CYCLOOXYGENASE-2 IN 
METASTATIC MELANOMA AFFECTS PROGRESSION FREE 
SURVIVAL 
 
4.1.1 Expression of COX-1 and COX-2 in human melanoma cell 
lines 
 
In order to gain further insights into the role of COXs in human 
melanoma we decided to evaluate the expression levels of both COX-1 
and COX-2 genes in normal human epidermal melanocytes (NHEM) and 
in different melanoma cell lines namely A375, SK-MEL-5, SK-MEL-28, 
WM35, WM983A, WM983B by using quantitative realt-time pcr analysis 
(qPCR). All cell lines showed an increased expression of COX-1 and COX-
2 as compared to NHEM. Indeed, COX-1 or COX-2 expression was always 
as minimum triplicated in all cell lines examined. What is of particular 
interest is the finding that the expression level of both COX-1 and COX-2 
appears to be reciprocal compensate within the melanoma cell lines 
(Figure 4.1.1A, 4.1.1B). Indeed, by looking at the Figure 4.1.1A and 
4.1.1B it appears that within each single cell line analyzed the ratio 
between the two isoforms is always about 1:2. The highest level of COX- 
2 expression was exhibited by SK-Mel-5 and thus this cell line was 
selected for the silencing experiments. 
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Figure 4.1.1: Expression of COX-1 and COX-2 in human  
melanoma cell lines. 
 
A. quantitative real-time PCR (qPCR) analysis to evaluate the expression 
levels of both COX-1 A. and COX-2 B. genes was performed on normal 
human epidermal melanocytes (NHEM) and on the melanoma cell lines 
A375, Sk-Mel-5, Sk-Mel-28, WM35, WM983A and WM983B. All human 
melanoma cell lines expressed both enzymes but with different level of 
expression. **P<0.01; ***P<0.001 vs NHEM. The housekeeping gene 
(ribosomal protein S16) was used as an internal control to normalize the 
ct values. 
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4.1.2 Selective inhibition of COX-2 activity and expression 
reduces human melanoma cell proliferation and invasiveness 
 
To investigate on the effect of COX-2 inhibition on melanoma cell 
proliferation we chose celecoxib, a selective COX-2 inhibitor, and 
compared the effect versus naproxen, a non selective COX inhibitor. 
Usually, concentrations of celecoxib required to induce apoptosis of 
cultured cells range from 25–100 μmol/L, thus we selected these 
concentrations to run our proliferation assays. As shown in Table 4.1.1 
celecoxib, but not naproxen, inhibited the growth of all cell lines tested 
in a time- and concentration-dependent manner. Celecoxib and 
naproxen did not inhibit proliferation of NHEM (data not shown). To 
further address the role of COX-2 versus COX-1 we transfected SK-Mel-5 
cells with siRNA for COX-2. The knockdown of COX-2 expression in cells 
after silencing was confirmed by western blot analysis (Figure 4.1.2A). 
As expected, COX-2 silencing significantly reduced cell invasiveness as 
compared to control (Figure 4.1.2B-4.1.2C). 
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Table 4.1.1: Effect of celecoxib and naproxen on A375, Sk-Mel-5 and 
Sk-Mel-28 melanoma cell proliferation 
 
Growth inhibition was measured using the MTT assay and is expressed 
as O.D. values at 24-48-72h. Celecoxib, but not naproxen, inhibited the 
growth of all melanoma cells at all times considered. Control (CTL). 
Experiments were run in triplicate. (**P<0.01; ***P<0.001 vs CTL). 
 
 
 
  
 
 
 
RESULTS 
77 
 
 
Figure 4.1.2: Silencing of COX-2 gene in Sk-Mel-5 cells significantly 
decreases melanoma cell invasiveness. 
 
Sk-Mel-5 cells were transfected with COX-2 siRNA to knockdown COX-2 
expression. A. transfection of Sk-Mel-5 cells by COX-2 siRNA resulted in 
marked reduction in the levels of COX-2 protein in cells as confirmed by 
western blot analysis. A significant reduction of cell invasiveness B, C. 
versus control siRNA-treated cells was observed. Each column is the 
mean ± SEM of three independent experiments, each performed in 
quadruplicate P<0.001 vs CTL. 
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4.1.3 B16-F10 murine cell induced melanoma is blunted in  
COX-2-/- mice 
 
To investigate the role of COX-2 also in melanoma development, we 
performed a reverse translational approach using COX-2-/- mice. Toward 
this aim, we used the most widely acknowledged experimental model to 
study melanoma development in vivo [160]. The tumour was implanted 
by subcutaneous injection of B16-F10 murine cells in the right flank of 
COX-2-/- mice and littermate controls C57Bl/6J. Tumour development in 
COX-2−/− mice was reduced in volume by 91% and in wet weight by 87% 
(P<0,001; n=10) (Figure 4.1.3A-C). 
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Figure 4.1.3: COX-2 is essential for melanoma development in mice. 
B16-F10 murine cells were subcutaneously injected into the right flank 
of COX-2-/- mice (n=10). C57Bl/6J mice were used as littermate control 
(n=10). A. representative image of tumour sizes. B. tumour 
development expressed as tumour volume. A marked and significant 
reduction in tumour volume by 91% was observed in COX-2–/– mice (○) 
(P < 0.001) as compared to littermate mice (•). C. tumour weight is 
significant reduced by 87% (P<0.001) in COX-2-/- mice (open square) as 
compared to littermate control (filled square). 
 
 
 
CHAPTER 4 
80 
 
4.1.4 Human melanoma samples 
 
The histological samples analysed were obtained from 45 lymph node 
melanoma metastases from the Biobank of the National Cancer Institute 
G. Pascale. The median age of patients was 50 years, female patients 
represented 44% (20/45). Primary tumour (pT) grade was distributed as 
follows: grade 1, 13.3% (6/45); grade 2, 26.7% (12/45); grade 3, 33.3% 
(15/45); grade 4, 26.7% (12/45). Ulceration was present in 35.6% 
(16/45) of the samples analyzed (Figure 4.1.4A). 
 
4.1.5 Higher COX-2 expression percentage in lymph node 
metastases correlates with negative progression free survival 
(PFS) outcome 
 
COX-2 expression was evaluated in all 45 samples. COX-2 
immunoreactivity was detected in 23 out of 45 (51%) lymph node 
metastases samples. A representative image of COX-2 negative staining 
is reported in Figure 4.1.4 (panel B, left) vs the positive staining (panel B, 
right). In order to verify if the percent of expression of COX-2 does play 
a role in melanoma malignancy evaluated as PFS, we compared negative 
samples vs samples with low COX-2 expression (COX-2low) set as cut off 
at up to ≤9%. As it can be seen in Figure 4.1.4 panel C, plotting samples 
with null COX-2 expression (blue line) vs COX-2low expression (≤9%; 
green line) there was no significant trend in PFS reduction.  
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Next, positive samples were separated into two new sub-groups, one 
where COX-2 expression was ≥10%, defined as COX-2high expression 
(green line), and a second where COX-2 expression was ≤9%, defined as 
COX-2low (blue line). When we plotted the data we found that the COX-
2high expression group showed a striking negative correlation with PFS. 
Indeed, patient with COX-2high had a reduction in PFS of 35 months 
(almost 3 years). 
 
4.1.6 BRAF and NRAS mutational status does not correlate with 
COX-2 expression in lymph node metastases 
 
In order to verify if melanoma most frequent mutations could influence 
the data outcome we characterized the NRASQ61 and BRAFV600E 
mutations. NRASQ61 was present in 8.9% of patients (n = 4/45), while 
activating BRAFV600E mutations, as expected, was more represented and 
found in 64.4% of patients (n = 29/45). Interestingly COX-2 expression 
did not correlate with BRAFV600E (p=0,768) or with NRASQ61 (p=0,934) 
mutational status (Figure 4.1.4 E-F). 
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Figure 4.14: Clinical-pathological characteristics of melanoma patients 
and tumours and relation to COX-2 expression. 
 
Frequencies are indicated in absolute values (percentage). COX-2 
median expression values, where indicated with (-), include negative 
samples and samples with low COX-2 expression (≤9%); where indicated 
a (+) include samples with high COX-2 expression (≥10%). Abbreviations: 
pT (primary tumour), M (male), F (female), Y (present), N (not present). 
B-D. Immunohistochemistry staining of COX-2 and Kaplan–Meier 
progression free survival curve stratified by median of COX-2 
expression. B. Immunohistochemistry staining of COX-2: left panel COX-
2 negative expression; right panel COX-2 positive expression. Images are 
20x. C. Kaplan–Meier progression free survival (PFS) curve of cases 
under the median of COX-2 expression stratified by not expressed (0%; 
n=12; blue line) and low COX- 2 expression (≤9%; n=5 green line) shows 
a not significant trend in PFS reduction. D. Kaplan–Meier PFS curve of 
cases stratified by low COX-2 expression (≤9%; n= 17; blue line), and 
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high COX-2 expression (≥10%; n=22; green line). Kaplan–Meier curve 
illustrate a significant correlation between COX-2 high expression and 
PFS. E-F. COX-2 expression and BRAFV600E and NRASQ61 mutational status. 
(E) Absence of correlation between COX-2 expression and BRAFV600E 
mutational status. (F) Absence of correlation between COX-2 expression 
and NRASQ61 mutational status. Data are expressed as BOX-plot 
distribution. 
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4.2 ATB-346, A NOVEL HYDROGEN SULFIDE-RELEASING 
ANTINFLAMMATORY DRUG, INDUCES APOPTOSIS OF 
HUMAN MELANOMA CELLS AND INHIBITS MELANOMA 
DEVELOPMENT IN VIVO 
 
4.2.1 ATB-346 inhibits human melanoma cell proliferation 
 
In the last few years, numerous physiological and pathophysiological 
roles have been proposed for the gasotransmitter hydrogen sulfide 
(H2S), along with a plethora of cellular and molecular targets [161, 162]. 
Recent studies indicate that H2S is also involved in the regulation of 
cancer biological processes and both pro- and anti-cancer effects have 
been described for this molecule [163-165]. Moreover, we have shown 
that the metabolic pathway leading to H2S endogenous production is 
involved in human melanoma progression [163]. An interesting class of 
new compounds has been developed in the last few years combining 
traditional NSAIDs with a chemical moiety that donates hydrogen 
sulfide. These molecules have been demonstrated to exhibit few if any 
damaging effects in the GI tract, despite producing suppression of 
prostaglandin synthesis and reduction of inflammation at least as 
effectively as the parent NSAID [166]. In the second phase of the 
project, we addressed the role played by COXs and H2S in preventing 
melanoma progression through a pharmacological modulation approach 
by using a new H2S-releasing derivative of naproxen, 2-(6- 
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methoxynapthalen-2-yl)-propionicacid 4-thiocarbamoyl phenyl ester 
(ATB-346), that inhibits COXs but also releases H2S [167]. 
In order to investigate on the potential anti-proliferative effect of ATB-
346 an MTT assay was carried out with ATB-346, TBZ (the H2S releasing 
moiety) and naproxen on a panel of human melanoma cells and on 
NHEM. In preliminary, dose-response experiments, the concentration of 
100 μM was selected. As shown in Table 4.2.1, only ATB-346 inhibited 
the growth of all cell lines tested in a time-dependent manner. Since the 
A375 cell line resulted to be the most sensitive to the anti-proliferative 
effect of ATB-346 it was selected as a tool. Incubation of A375 cells with 
ATB-346 (100 μM) for 24, 48 or 72 h caused an inhibition of cell 
proliferation by 38.2%, 63.2% and 66%, respectively (P < 0.001) (Table 
4.2.1). Neither TBZ nor naproxen reduced A375 cell proliferation 
significantly at any time or concentration tested. None of the drugs 
inhibited the proliferation of NHEM up to 100 μM (Table 4.2.1). 
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Table 4.2.1: Effect of ATB-346, Naproxen and TBZ on NHEM and on 
A375, Sk-Mel-5, Sk-Mel-28 and PES43 melanoma cells proliferation. 
 
Growth inhibition was measured using the MTT assay and is expressed 
as O.D. values at 24–48–72 h. Only ATB-346 inhibited the growth of all 
melanoma cells at all times that were examined. Experiments were run 
in triplicate, each performed in quadruplicate (**P < 0.01; ***P < 0.001 
vs CTL). 
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4.2.2 ATB-346 induces apoptosis of human melanoma cells 
 
A375 human melanoma cells were treated with ATB-346, TBZ or 
naproxen (100 μM for 24 and 48 h) and apoptosis was determined by 
annexinV/PI staining, which detects the externalization of 
phosphatidylserine (PS), a characteristic feature of cells entering 
apoptosis. This dual staining distinguishes between unaffected cells 
(unlabeled; quadrant 3, Fig. 4.2.1A), early apoptotic cells (annexinV 
positive; quadrant 4, Fig. 4.2.1A), late apoptotic cells (annexin V pos-
itive, PI positive; quadrant 2, Fig. 4.2.1A), and necrotic (PI positive; 
quadrant 1, Fig. 4.2.1A). As shown in Fig. 4.2.1B only ATB-346 induced 
apoptosis of A375 cells in a time-dependent manner (18% and 24% at24 
and 48 h respectively). The pro-apoptotic effect of ATB-346 was 
confirmed by the time-dependent cleavage of caspase 3, the main 
effector caspase, and of its substrate poly (adenosine diphosphate-
ribose) polymerase (PARP) (Fig. 4.2.1C). 
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Figure 4.2.1: ATB-346 induces apoptosis of human melanoma cells. 
 
(A) Cells were treated with ATB-346, naproxen or TBZ (100 μM) at 
different time points and apoptosis was determined by flow cytometry 
analysis. Apoptosis was determined by annexin V/propidium iodide (PI) 
staining, which detects the externalization of phosphatidylserine (PS). 
This dual staining distinguishes between unaffected cells (unlabeled; 
quadrant 3, Q3), early apoptotic cells (annexin V positive; quadrant 4, 
Q4), late apoptotic cells (annexin V positive, PI positive; quadrant 2, Q2), 
and necrotic (PI positive; quadrant 1, Q1). Treatment of A375 cells for 
24–48 h with ATB-346 (100 μM) resulted in a time-dependent induction 
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of apoptosis. (B) Quantitative analysis of apoptosis at various time 
points of exposure to ATB-346, naproxen or TBZ, showing that at 48 h 
almost 25% of cells treated with ATB-346 exhibit markers of late 
apoptosis. Experiments (n = 3) were performed in triplicate. (C) Western 
blot analysis of caspase 3 and PARP in A375 whole-cell lysates. A375 
cells were incubated with ATB-346, naproxen or TBZ 100 μM for 24 h 
and a time-dependent cleavage of caspase 3 and of its substrate PARP 
were observed. 
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4.2.3 ATB-346 inhibits NF-𝜅B activation and down-regulates  
NF-𝜅B dependent anti-apoptotic genes 
 
In malignant melanoma NF-𝜅B is constitutively activated following I𝜅B 
inhibitor protein degradation. Indeed, the active NF-𝜅B complex 
containing the p65 subunit promotes the expression of several anti-
apoptotic proteins such as inhibitor of apoptosis (IAP) and Bcl-2 family 
contributing to cell survival and apoptosis escape [168]. Incubation of 
A375 cells with ATB-346 (100 μM) caused inhibition of I𝜅Bα degradation 
(Fig. 4.2.2A) and of NF-𝜅B nuclear translocation as demonstrated by a 
reduction in band intensity of the p65 subunit (Fig. 4.2.2B). We next 
evaluated the expression of two NF-𝜅B-dependent anti-apoptotic 
proteins, X-chromosome-linked inhibitor of apoptosis protein (XIAP) and 
Bcl-2. As shown in Fig. 4.2.2C-D ATB-346 reduced the expression of the 
anti-apoptotic genes considered, thus confirming the involvement of 
NF-𝜅B. PI3K/Akt is one of the most frequently deregulated pathways in 
melanoma [169]. This pathway plays an important role in melanoma 
development and progression and is involved in the mechanism of 
resistance to targeted therapy [170]. In addition, it has been reported 
that Akt phosphorylates the NF-𝜅B subunit p65, increasing the binding 
of the NF-𝜅B complex to DNA [171]. Treatment of A375 cells with ATB-
346 (100 μM) significantly (P < 0.01) reduced p-Akt band intensity (Fig. 
4.2.2E), suggesting a specificity of the effect on the activation of the 
Akt/p-Akt/NF-𝜅B signaling pathway. 
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Figure 4.2.2: ATB-346 inhibits NF-𝜅B activation, down-regulates NF-𝜅B-
dependent anti-apoptotic genes and pro-survival pathways in 
melanoma cells. 
 
(A) Western blot analysis carried out on the cytosolic extracts obtained 
from A375 cells treated with ATB-346 (100 μM) for 15, 30, or 60 min 
shows an inhibition of I𝜅Bα degradation at the earliest time points. (B) 
Nuclear extracts from control-treated and ATB-346-treated A375 cells 
collected at 6–24 h were analyzed by Western blot for NF-𝜅B activation. 
The A375 cell line displayed a constitutively high nuclear translocation 
of p65, that was reduced by ATB-346 at 24 h. (C–E) Western blot 
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analysis and relative densitometry of XIAP, Bcl-2 and phospho- and total 
Akt carried out on A375 cells treated with ATB-346 (100 μM) for 6–24 h. 
ATB-346 decreased the expression of both the anti-apoptotic genes 
analyzed as well as p-Akt band intensity; ***P < 0.001; **P < 0.01; *P < 
0.05 vs control (CTL). Actin was detected as a loading control. 
Experiments (n = 3) were performed in triplicate. 
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4.2.4 ATB-346 inhibits growth of melanoma tumors in vivo and 
reduce plasma levels of melanoma-associated chemokines 
 
In order to define if the effects described above translate in an in vivo 
setting we subcutaneously implanted B16-F10 murine melanoma cells in 
C57BL/6 mice. Tumor-bearing mice were treated twice daily with ATB-
346, naproxen or TBZ, all drugs were administered orally at an 
equimolar dose of 43 μmol/kg. As shown in Fig. 4.2.3A, mice receiving 
ATB-346 displayed a reduction of tumor size by 61% (0.311 ± 0.05 cm3; 
P < 0.01) as compared to control mice (0.806 ± 0.1 cm3) 14 days after 
tumor implantation. Naproxen and TBZ reduced tumor size by 14% and 
34% respectively (0.691 ± 0.156 cm3and 0.531 ± 0.086 mean tumor 
volume). Also tumor wet weight was significantly reduced by ATB-346 
by 62% (379.5 ± 71 mg mean weight; P < 0.01) as compared to control 
mice (987.3 ± 190.3 mg mean weight). Naproxen and TBZ also reduced 
tumor wet weight by 24% and 37% respectively (753.8 ± 160.5 and 
620.4 ± 87.5 mg mean weight; Fig. 4.2.3B). Among chemokines CXCL1, a 
member of the CXC chemokine subfamily, has been associated with 
metastatic melanoma [172]. As shown in Fig. 4.2.3C, only ATB-346 (43 
μmol/kg) induced a significant reduction of CXCL1 plasma levels by 67% 
(83 ± 12 pg/mL; P < 0.01) as compared to control mice (255 ± 48.4). On 
the other hand, neither naproxen nor TBZ, at equimolar doses, reduced 
CXCL1 plasma levels (135 ± 65 and129 ± 30 pg/mL respectively). 
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Figure 4.2.3: ATB-346 inhibits tumor growth in vivo and reduces 
plasma levels of thechemokine CXCL1. 
 
(A) ATB-346, naproxen or TBZ (43 μmol/kg) were given orally to 
mice. Control mice received vehicle only. Tumor volume was 
monitored on the indicated days. The average tumor volume with 
standard error is plotted against the days after tumor implant. ATB-
346 significantly reduced tumor volume (**P < 0.01 vs control, n = 
8; day 14).  
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(B) ATB-346 significantly inhibited tumor weight (**P < 0.01 vs 
control, n = 8).  
(C) ATB-346 induced a significant reduction of CXCL1 plasma levels 
(**P < 0.01 vs control, n = 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
96 
 
4.3 PTGS2 KNOCKDOWN BY CRISPR/CAS9 TECHNOLOGY INHIBITS 
AGGRESSIVENESS AND PROGRESSION OF MELANOMA 
 
4.3.1 Generating a Knockdown PTGS2 Melanoma Cell Line Using 
the CRISPR/Cas9 System 
 
For the last phase of the project we decided to establish if the role of 
COX-2 was played predominantly in the microenvironment rather than 
in tumor cells. For this purpose we deleted COX-2 in B16/F10 murine 
melanoma cells by using clustered regularly interspaced short 
palindromic repeats-CRISPR associated nuclease 9 (CRISPR/Cas9) 
technology, a natural bacterial adaptive immune mechanism which is 
now being utilized as a novel innovative technology to quickly perform 
genetic manipulations [173]. We co-trasfected B16/F10 murine 
melanoma cells with guide-RNAs targeting the PTGS2 gene or scramble 
negative control together with a Cas-9 and a donor construct containing 
the puromycin resistance gene. We chose to delete one allele to assure 
a knockdown rather than a complete knockout which might have been 
noxious. After clonal selection with puromycin, PTGS2 knockdown was 
detected by quantitative real-time PCR (qPCR), which was confirmed at 
the protein level by Western blotting (Figure 4.3.1A-B). Cells were then 
selected and used for next experiments. 
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Figure 4.3.1: Knockdown effect of PTGS2 CRISPR/Cas9 in B16/F10 
murine melanoma cells. 
 
A. B16/F10 cells were transfected with PTGS2 CRISPR/Cas9 
(B16/PTGS2Δ) and Scrambe (B16/Scramble) at a concentration of 2 μg 
(1 μg gRNA or Scrambled control with 1 μg donor). Cells were harvested 
48 hours after the transfection, and were sub-cultured 5–7 times before 
puromycin selection. The knockdown effect at the PTGS2 mRNA level 
was determined using quantitative real-time PCR (qPCR). Data are 
shown as mean ± SEM (***P<0.001 vs B16/Scramble). B16/F10, 
negative control without plasmid. B. The silencing effect of PTGS2 
CRISPR/Cas9 at the protein level was determined using western blot 
analysis. 
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4.3.2 PTGS2 Knockdown downregulates the proliferative 
potential in melanoma cells 
 
In order to address whether PTGS2 is essential for the proliferation of 
melanoma cells, we next examined the proliferation rate of B16/F10 
wild-type, B16/PTGS2Δ and B16/Scramble melanoma cells. Cell growth 
was determined at 24, 48 and 72 hours. B16/PTGS2Δ cells 
demonstrated slower growth rate (Table 4.3.1) compared with B16/F10 
and B16/Scramble. This result suggested the crucial role of PTGS2 in the 
proliferation of melanoma cancer cells, and that suppression of PTGS2 
lead to downregulation of cell proliferation. 
 
 
 
Table 4.3.1: PTGS2 knockdown downregulates proliferation rate. 
 
Proliferation rate was measured using the MTT [3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyl tetrazolium bromide] assay and is expressed as OD 
values at 24-48-72h. B16/PTGS2Δ showed a slower growth rate at all 
times considered. Experiments were run in triplicate, each performed in 
quadruplicate. (**P<0.01; ***P<0.001 vs B16/Scramble). B16/F10, 
negative control without plasmid. 
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4.3.3 PTGS2 Knockdown thwarts cell motility and invasion 
 
To gain further insight on the role of PTGS2 in vitro we decided to use a 
classic wound healing assay in order to analyze the cell motility of 
melanoma cancer cells. Thus, the cell monolayer was scratched and cells 
migrating to the wound area were monitored at different time points. 
B16/PTGS2Δ melanoma cells showed a wider wound area 24 hours after 
wound generation compared to B16/F10 wild-type and B16/Scramble 
and required a longer time to fill in the wound area, demonstrating a 
defect in migration (Figure 4.3.2A-B). Since both cell migration and 
invasion have important role in the diffusion of cancer cells and the 
development of metastases, we further investigated the cell 
invasiveness using in vitro invasion assay that was done by using Boyden 
chambers coated with matrigel. Cells that invaded to the bottom of the 
chamber were fixed, stained and counted. The results demonstrated 
that B16/PTGS2Δ were less invasive than B16/F10 and B16/Scramble 
(Figure 4.3.2C-D). Together, these data indicate that knockdown of 
PTGS2 decreases the invasiveness and the migration of melanoma 
cancer cells. 
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Figure 4.3.2: Knockdown of PTGS2 inhibited motility and invasion 
ability of B16/F10 melanoma cells. 
 
A. The migration potential of B16/PTGS2Δ was evaluated by Wound 
healing assay. Cells were wounded and monitored with a microscope for 
12 and 24 hours.  
B. The migration was determined by the rate of cells filling the scratched 
area and the result represented as mean ± SEM (n = 3). (*P < 0.05; 
**P<0.01 vs B16/Scramble).  
C. Cell invasion was determined using Boyden chambers coated with 
Matrigel. Cells were plated in the upper chamber in serum-free 
medium. Cells migrated through pores were fixed with 4% 
formaldehyde and stained with 0.1% crystal violet. The filters were 
examined microscopically and cellular invasion was determined by 
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counting the number of stained cells on each filter in at least 4– 5 
randomly selected fields.   
D. Resultant data are presented as mean of invaded cells ± SEM 
/microscopic field of three independent experiments (**P<0.01 vs 
B16/Scramble).  
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4.3.4 PTGS2 Knockdown inhibits focus formation of melanoma 
cells 
 
To test whether PTGS2 knockdown in B16/F10 melanoma cells affects 
the clonogenic potential which correlates with the capacity of cells to 
produce progeny and tumor formation in vivo [174], we used a focus 
formation assay. Thus, B16/F10, B16/PTGS2Δ and B16/Scramble cells 
were seeded into six-well plates and incubated for 14 days to allow 
focus formation. The cells were fixed, stained with crystal violet, and 
counted. As shown in Figure 4.3.3, B16/PTGS2Δ cells exhibited smaller 
focus diameter as well as focus numbers compared to B16/F10 and 
B16/Scramble. These data indicated that inhibition of PTGS2 
significantly decreases the cell focus formation potential and thus the 
development and progression of tumors in vivo. 
 
 
 
 
 
 
 
 
 
 
RESULTS 
103 
 
 
 
Figure 4.3.3: PTGS2 knockdown inhibits clonogenic growth. 
 
A. Cells were seeded in six-well plate, and the medium was changed 
every two days. Cells cultured for 14 days were washed twice with 
1xPBS, fixed by 4% paraformaldehyde, and stained with 0.5% crystal 
violet. Images of the colonies were obtained with a digital camera.  
B. Foci containing ≥50 cells were counted and the result represented as 
mean ± SEM (n = 3). (***P<0.001 vs B16/scramble). B16/F10 negative 
control without plasmid. 
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4.3.5 PTGS2 Knockdown inhibits the development of cutaneous 
melanoma In Vivo and reduces CXCL1 plasma levels. 
 
In order to define if the effects described above translate in an in vivo 
setting we subcutaneously implanted B16/F10 wildtype, B16/PTGS2Δ 
and B16/Scramble melanoma cells in C57BL/6 mice. As show in Figure 
4.3.4A mice implanted with B16/PTGS2Δ displayed a slighted reduction 
of tumor size by ~ 30% (0.357 ± 0.04 cm3; P < 0.05) as compared to 
B16/F10 and B16/Scramble implanted mice (0.500 ± 0.02 cm3; 0.520 ± 
0.03 cm3 respectively) 14 days after tumor implantation. Also tumor 
weight were slightly reduced in B16/PTGS2Δ implanted mice by 20 - 
30% (469 ± 15.8 mg mean weight; P <0.05) (Figure 4.3.4B) as compared 
to B16/F10 and B16/Scramble implanted mice (669 ± 68 mg mean 
weight; 589 ± 53 mg mean weight respectively). Moreover, we also 
evaluated CXCL1 plasma levels. As show in Figure 4.3.4C only 
B16/PTGS2Δ implanted mice showed a significant reduction of CXCL1 
plasma levels by 48% and 37% (359 ± 31 pg/ml) as compared to B16/F10 
and B16/Scramble mice (689 ± 131 pg/ml; 568 ± 59 pg/ml respectively). 
Taken together, the in vivo data suggests that inhibition of PTGS2 
reduces the development and aggressiveness of cutaneous melanoma 
by downstream pathways involving chemokines. Nonetheless, our 
results demonstrate that PTGS2 is relevant but not unique in determine 
the complex network between the microenvironment and tumors. 
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Figure 4.3.4: Knockdown of PTGS2 inhibits tumor growth in vivo and 
reduces plasma levels of the chemokine CXCL1. 
 
A. B16/F10 (🔴), B16/PTGS2Δ (🔺) or B16/Scramble ( ) were 
subcutaneously implanted in mice. Tumor volume was monitored on 
the indicated days. The average tumor volume with standard error is 
plotted against the days after tumor implant. B16/PTGS2Δ significantly 
reduced tumor volume (*P < 0.05 vs B16/Scramble, n = 8; day 14).  
B. B16/PTGS2Δ significantly inhibited tumor weight (*P < 0.05 vs 
B16/Scramble, n = 8; day 14). C. B16/PTGS2Δ induced a significant 
reduction of CXCL1 plasma levels (*P < 0.05 vs B16/Scramble, n = 8; day 
14). Data are shown as mean ± SEM. 
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4.4 MicroRNA-143-3p INHIBITS GROWTH AND INVASIVENESS OF 
MELANOMA CELLS BY TARGETING CYCLOOXYGENASE-2 AND 
INVERSELY CORRELATES WITH MALIGNANT MELANOMA 
PROGRESSION 
 
4.4.1 miR-143-3p is downregulated in melanoma cell lines 
 
Recent evidences demonstrated that microRNAs (miRNAs), that play a 
critical role in the post-transcriptional regulation of gene expression, 
also regulate many aspects of tumor progression including cellular 
migration, proliferation and angiogenesis [155, 156]. Significant 
deregulation of miRNAs expression profiling between tumor cells and 
cells derived from normal tissue has been found, indicating that they 
function as either oncogenes or tumor suppressors in various cancers 
including melanoma [175-177]. Over the last years, several miRNAs have 
been demonstrated to be important direct regulators of COX-2 gene 
expression in cancer or non cancer cells [157]. In this respect, it has 
been shown that miR-101 inhibits the prostate cancer cell invasiveness 
by negatively regulating the COX-2 pathway [178]; miR-26b regulates 
COX-2 expression both in desferrioxamine-treated carcinoma of 
nasopharyngeal epithelial cells [179] and in breast cancer [180]. Another 
interesting candidate targeting COX-2 is miR-143-3p that is dysregulated 
in many cancers [181, 182]. In particular, its decreased expression is a 
marker of high malignancy and poor prognosis. However, the potential 
role of miR-143-3p in human melanoma remains unknown. Thus, 
following our results achieved during the first phases of the project we 
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decided to investigate on miR-143-3p-mediated COX-2 regulation of 
expression in human melanoma cells. In order to investigate the 
potential role of miR-143-3p in melanoma cells, we measured its 
expression levels in different human melanoma cell lines (WM1862, 
WM983A, A375, SKMel 28). Normal Human Epidermal Melanocytes 
(NHEM) were used as control. By means of quantitative PCR, we found 
that in melanoma cell lines the expression levels of miR-143-3p was 
significantly lower than control (NHEM) cells (p < 0.001) (Fig. 4.4.1A). 
To gain further inside on the role of miR-143-3p in melanoma cells, we 
transiently transfected A375 cells with control (scramble) or miR-143-3p 
sequences. After transfection, in both control and miR-143-3p-
transfected cells, we evaluated the cell proliferation and apoptosis. 
Firstly, using qPCR, we examined the expression of miR-143-3p in 
transfected cells, and as expected it was significantly higher than control 
cells (Fig. 4.4.1B). Moreover, in miR-143-3p-transfected A375 cells, we 
found a reduced proliferation in a time dependent manner (12% and 
30% at 48 and 72 h, respectively; Fig. 4.4.1C) associated with an 
increased apoptosis (43%; Fig. 4.4.1D) as compared to the scramble-
transfected cells.  
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Figure 4.4.1: Expression levels of miR-143-3p in human melanoma cell 
lines and its effect on melanoma cell proliferation and apoptosis. 
 
(A) Relative expression of miR-143-3p in four human melanoma cell 
lines (WM1862, WM983A, A375, SKMel28) compared with NHEM. (B) 
A375 cells were transfected with scramble or miR-143-3p mimics for 48 
h. The successful overexpression of miR-143-3p was detect by qRT-PCR 
analysis. (C) MTT assay was performed to analyze the effect of miR-143-
3p transfection on A375 cell proliferation at the indicated time points. 
(D) The influence of miR-143-3p on cell apoptosis was analyzed using 
ApoTox‐Glo Triplex Assay. Data are shown as mean ± SEM (*P < 0.05, 
***P < 0.001). 
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4.4.2 miR-143-3p suppresses migration and invasion of human 
melanoma cells 
 
In addition to the findings described above, we evaluated the 
clonogenic ability, migratory potential and invasiveness of A375 cells 
following miR-143-3p-mimics transfection. As shown in Fig. 4.4.2A–B 
the clonogenic ability of A375 cells was markedly reduced following 
miR-143-3p-mimics transfection. Moreover, we found that the number 
of migratory (Fig. 4.4.2C and D; p < 0.01) and invasive (Fig. 4.4.2E and F; 
p < 0.001) miR-143-3p-transfected A375 cells, was significantly reduced 
compared to scramble-transfected cells. 
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Figure 4.4.2: Effect of miR-143-3p on melanoma cell colony formation, 
migration and invasion. 
 
A375 cells were transfected with scramble or miR-143-3p mimics. (A) 
Representative photographs and average number (B) of A375 cell 
colony formation. (C) Representative photographs and average number 
(D) of migratory A375 cells. (E) Representative photographs and average 
number (F) of invasive A375 cells. Data are shown as mean ± SEM (**P < 
0.01, ***P < 0.001). 
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4.4.3 miR-143-3p targets the 3’-UTR of COX-2 
 
To explore the mechanism(s) involved in miR-143-3p-mediated tumor 
suppression, putative downstream gene targets of miR-143-3p were 
searched using prediction programs TargetScan, miRanda, PicTar. 
Therefore, by means of bioinformatics analysis, we found putative 
binding sites of miR-143-3p in the three prime untranslated region (3′-
UTR) of PTGS2 gene (position 1711/1717) (Fig. 4.4.3A–B). Luciferase 
reporter assay was then performed to prove the functional binding of 
miR-143-3p and COX2 gene at the predicted sites. In particular, 
luciferase reporters carrying a wild-type PTGS2 3′UTR sequence 
including the miR-143-3p binding site (PTGS2- 3′UTRwt) or a mutated 
3′UTR (PTGS2-3′UTRmut) were used (Fig. 4.4.3C). Our results indicated 
that in A375 cells co-transfected with PTGS2- 3′UTRwt and miR-143-3p 
mimics there was a significant reduction of luciferase activity compared 
with that of PTGS2-3′UTRmut-transfected cells (Fig. 4.4.3C). In addition, 
in miR-143-3p-transfected A375 cells, we observed a decreased of COX-
2 mRNA and protein expression (Fig. 4.4.3D–E). In conclusion, these 
results clearly demonstrated that miR-143-3p functionally suppresses 
the transcriptional activity of COX-2 gene. 
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Figure 4.4.3: Prediction of PTGS2 as a target of miR-143-3p. 
 
(A) Complementary 7mer-A1 seed match between miR-143-3p and the 
3′UTR of PTGS2 as predicted by TargetScan software. (B) Conservation 
of the 7mer-A1 seed of miR-143-3p in the 3′UTR of PTGS2 in indicated 
organisms. (C) A dual-luciferase reporter system analysis was performed 
on A375 cells co-transfected with the wild-type/mutant 3′UTR 
sequences of PTGS2 and scramble or miR-143-3p mimics. (D–E) qRT-PCR 
and western blot were performed to detect the expression of COX-2 
upon transfection with miR-143-3p mimics. Data are shown as mean ± 
SEM (*P < 0.05, ***P < 0.001). 
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4.4.4 miR-143-3p transfection decreases PGE2 levels in A375 
cells 
 
To further confirm that COX-2 is directly targeted by miR-143-3p we 
evaluated PGE2 levels in cell culture supernatants. Transfecting A375 
cells with miR-143-3p mimics significantly decreased the concentration 
of PGE2 by about 50% compared with scramble (Fig. 4.4.4). 
 
 
Figure 4.4.4: Effect of miR-143-3p on PGE2 secretion 
 
PGE2 concentrations in A375 cell culture supernatants upon 
transfection 
with miR-143-3p mimics or scramble. Data are presented as the mean ± 
SEM (**P < 0.01). 
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4.4.5 Expression of miR-143-3p in human primary melanoma 
lesions 
 
Since we showed in the first phase of the project a correlation between 
high levels of COX-2 expression and poor survival in melanoma patients, 
in this last phase we analyzed the expression of miR-143-3p in human 
melanoma surgical specimens. We selected ten primary lesions and 
twenty metastasis showing high levels of COX-2 expression. Our results 
revealed a robust reduction of miR-143-3p expression between human 
melanoma samples vs healthy melanocytes (Fig. 4.4.5A). Moreover we 
demonstrated that COX-2 expression correlates with miR-143-3p 
expression level in each subject analyzed (Fig. 4.4.5B). 
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Figure 4.4.5: Expression levels of miR-143-3p in human melanoma 
specimens and correlation with COX-2 expression 
 
(A) Relative expression of miR-143-3p in primary melanoma lesions and 
metastases compared with normal human epidermal melanocytes. Data 
are shown as mean ± SEM (*P < 0.05). (B) Cutoff of COX-2 expression 
was established according to the mean of expression (33%). Data are 
shown as mean ± SEM (**P < 0.01). 
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CHAPTER 5: DISCUSSION 
Melanoma remains one of the most invasive and drug-resistant cancers 
with a consistently increasing of incidence and mortality rates [183]. A 
better understanding of the molecular mechanisms behind melanoma 
development and progression is needed to develop more effective 
therapies and to identify new markers to predict disease behavior. The 
effectiveness of the novel treatments for cancer patients are based on 
targeting the pro-tumorigenic factors instead of the single tumor cell. In 
the TME secreted factors like cytokines, growth factors, growth 
modulators, extracellular matrix proteins and matrix proteases as well 
as mesenchymal and inflammatory cells interact with tumor cells to 
increase tumor formation and metastasis [184]. Inflammation underlies 
this microenvironment and it is considered the strongest supporter in 
tumorigenesis. In particular, it has been shown that COX-2 and its 
product PGE2 are expressed at high levels in a variety of cancers 
promoting their growth [57, 185, 186]. Several lines of evidence indicate 
that COX-2 is strongly expressed also in malignant melanoma and it may 
be correlated with the development and progression of disease [150-
153]. Based on these preliminary data we decided, for the first phase of 
the project, to gain further insights into the role of COXs in melanoma 
by using different human melanoma cell lines. All cell lines showed an 
increased expression of COX-1 and COX-2 as compared to NHEM. 
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The level of expression of both enzymes varied among the cell lines 
studied suggesting that expression of COX-1 vs COX-2 appears to be 
reciprocal compensate within melanoma cells. In other words, when 
COX-1 expression is lower COX-2 is doubled and viceversa. However, in 
order to further define the major role of COX-2 vs COX-1 we evaluated 
the effect of COX-2 inhibition on melanoma cell proliferation. We 
choose as selective COX-2 inhibitor celecoxib and compared its effect to 
naproxen, a NSAID less than 5-fold selective for COX-2 [187, 188]. 
Celecoxib was selected since it is known to exhibit the greatest potency 
among COX inhibitors for growth inhibition [189]. Celecoxib, but not 
naproxen, inhibited the growth of all cell lines tested in a time- and 
concentration-dependent manner further supporting a major role for 
COX-2 in melanoma development. We next transfected SK-Mel-5 cells 
with siRNA for COX-2. As expected COX-2 silencing significantly reduced 
both cell proliferation and invasiveness as compared to control siRNA. 
Thus, in melanoma cell lines, COX-2 increased expression appears to be 
a “cellular tool” to increase their ability to invade the host. In order to 
investigate on the role of COX-2 in melanoma development also in vivo, 
we performed a reverse translational approach by using COX-2-/- mice. 
The lack of COX-2 almost blunted tumour development as opposite to 
background mice. This finding, attained with mice with a competent 
immune system, supports a key role for COX-2 vs COX-1 in melanoma 
development. 
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However, since the removal of COX-2 gene does not completely abolish 
tumour development, COX-1 residual contribute cannot be ruled out. In 
conclusion we evaluated the expression of COX-2 on 45 human lymph 
node metastases from different primary melanoma sites, indicating that 
the COX-2 expression level influences human melanoma malignancy. 
However, if data are analyzed to search a close correlation between 
COX-2 expression and PFS, the results obtained do not give a clear 
outcome. Indeed, if the samples analyzed are simply divided into COX-2 
negative- vs COX-2 positive the correlation with PFS is present but it is 
not remarkable. By performing a series of differential analysis on the 
percent of expression of COX-2 we found that when samples analyzed 
were separated into two sub-groups, namely COX-2high where COX-2 
expression was ≥10%, and COX-2low where COX-2 expression was ≤9%, a 
striking difference was evident. Actually, the COX-2high expression group 
showed a significant negative correlation with PFS which was reduced 
by 35 months (almost 3 years) in COX-2high patients. Therefore, the level 
of COX-2 expression, determined as COX-2high, represents a trade off 
versus a COX-2 negative significant contribute to melanoma malignancy. 
It is possible to hypothesize that COX-2high tumour promoting effect may 
be driven by COX-2 derived PGE2 as a potent tumour immune escape 
mechanism associated with enhancement of cancer cell survival, 
growth, migration, invasion, angiogenesis, and immunosuppression 
[50]. 
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Recently, Zelenay et al., by using an arbitrary cut off of microarray 
expression data in melanoma biopsies, demonstrated a positive 
correlation among COX-2 and the levels of some specific tumour 
promoting factor [190]. The same mechanism may apply to our COX-
2high samples. In fact, we can speculate that, the overcoming of a specific 
threshold in COX-2 expression, allows the tumour to become more 
‘aggressive’ with a higher probability of malignant metastasis. In order 
to verify if melanoma most frequent mutations could influence the data 
outcome we characterized the NRASQ61 and BRAFV600E mutations in the 
samples analyzed. COX-2 expression neither correlated with BRAFV600E 
nor with NRASQ61 mutational status. Therefore, since COX-2high/PFS 
correlation is affected by neither NRASQ61 nor BRAFV600E mutations it 
appears that COX-2high is a variant non affected by these mutations, at 
least in our study. In conclusion, the first phase of the project, showed 
that COX-2 plays a role also in melanoma development as demonstrated 
in vivo by using COX-2-/- mice. Moreover, its expression may become an 
useful diagnostic tool in defining melanoma malignancy as well as argue 
for a possible therapeutic use of NSAID as add on therapy in selected 
cases.  
The current clinical approach to melanoma is focused on reducing the 
probability of resistance that is the main therapeutic problem. Indeed, it 
is now widely accepted that multiple important targets will need to be 
simultaneously besieged in order to ensure an enduring effect. 
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To achieve this purpose different approaches have been used and are 
currently in clinical development as the “combo therapy” where 
different checkpoints of the melanoma development are targeted. ATB-
346 is a novel hydrogen sulfide-releasing derivative of naproxen with 
reduced GI toxicity [167]. It has been recently shown that ATB-346 
exerts superior chemopreventive effects to those of naproxen, while 
sparing the gastrointestinal tract of the injury normally associated with 
use of the parent drug in experimental colorectal cancer [191, 192]. 
Thus, for the second phase of the project, we further broaden the role 
played by COXs in preventing melanoma progression by using this new 
drug demonstrating, both in vitro and in vivo, its ability to inhibit 
melanoma progression. In this study, naproxen and TBZ (the H2S 
releasing moiety) were used at equimolar doses. The dose of ATB-346 
and naproxen employed have been previously shown to produce 
equivalent inhibition of prostaglandin and thromboxane synthesis [167]. 
To test ATB-346 activity we used a panel of human melanoma cells. We 
found that only ATB-346, but neither naproxen nor TBZ, inhibited the 
proliferation of human melanoma cell lines. In addition, ATB-346 did not 
modify NHEM proliferation, thus indicating a selectivity of action toward 
melanoma cells. Among the cell lines used the A375 was the most 
sensitive to the anti-proliferative effect of ATB-346 and for this reason 
was selected to carry on the in vitro characterization of ATB-346. 
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The anti-proliferative effect of ATB-346 involved apoptosis of human 
melanoma cells as defined in the cytofluorimetric studies. Indeed, ATB-
346 induced apoptosis of A375 cells and this effect implicated the 
cleavage of caspase-3, the main “effector” caspase in the apoptotic 
pathway. Conversely, TBZ and naproxen, at the equimolar concentration 
tested, did not induce apoptosis of human melanoma cells, suggesting 
that the effect observed was due to ATB-346 rather than to the parent 
drug or to the hydrogen sulfide-releasing moiety (TBZ). Constitutive NF-
𝜅B and activated Akt expression have been described in melanoma and 
have been associated with increased survival of cancer cells and 
resistance to chemotherapy [193, 194]. Indeed, it is well known that the 
PI3K/Akt is one of the most frequently deregulated pathways in 
melanoma [169] playing an important role in development and 
progression of this deadly form of cancer, as well as being involved in 
the mechanism of resistance to targeted therapy [170]. Therefore 
following on characterizing ATB-346 we have investigated on the 
possible involvement of these two pathways. We found that ATB-346 
inhibited I𝜅Bα degradation and this effect was associated to the 
inhibition of NF-𝜅B nuclear translocation and activation in line with our 
previous finding obtained using H2S donors [163]. ATB-346 inhibited Akt 
phosphorylation and activation, too. These data are of particular 
interest considering that a growing body of evidence indicates that Akt, 
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along with its downstream targets, constitute the major cell survival 
pathway in melanoma.  
Since ATB-346 also greatly decreased the expression of the anti-
apoptotic proteins XIAP and Bcl-2, we can speculate that the effect 
observed with ATB-346 is driven by inhibition of NF-𝜅B activation and 
Akt phosphorylation that in turn down-regulates XIAP and Bcl-2 
expression and activation [195]. The lack of effect of TBZ and naproxen, 
at the doses used in this study, strongly suggests that the ATB-346 effect 
relies on the simultaneous targeting of multiple key signaling pathways 
implicated in melanoma development, such as NF-𝜅B activation and Akt 
phosphorylation, obtained through the synchronized release of H2S and 
COX inhibition. In order to support this evidence, we designed a 
translational in vivo pre-clinical approach by using an animal model of 
cutaneous melanoma. Treatment of mice with ATB-346 significantly 
reduced tumor volume and weight. Naproxen and TBZ at the equimolar 
doses only slightly reduced tumor volume. Chemokines play a vital role 
in tumor progression and metastasis and are involved in the growth of 
many cancers including melanoma [196]. In particular, CXCL1 is up-
regulated in melanoma cells, and it is involved in pathogenesis of 
melanoma [172]. When we measured CXCL1 plasma levels of tumor-
bearing mice treated with ATB-346 we found that they were 
significantly down-regulated as compared to control mice. In conclusion, 
the second phase of the project demonstrates that the combination of 
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inhibition of cyclooxygenases and delivery of H2S by ATB-346 may offer 
a promising alternative to existing therapies for melanoma. 
Our study demonstrates that in human melanoma cells, ATB-346 1) 
inhibits cell proliferation; 2) induces apoptosis; 3) this apoptotic effect 
involves: a) the suppression of pro-survival pathways associated to NF-
𝜅B transcription activity as demonstrated by the decreased expression 
of, XIAP and Bcl-2 and b) inhibition of the activation of Akt downstream 
signaling pathways. Mechanistically, ATB-346 inhibited melanoma cell 
survival by targeting the COX and PI3K/Akt pathways, which decreased 
cellular proliferation and triggered apoptosis. Oral administration of 
ATB-346 retarded the growth of melanoma tumors by up to 70% 
without affecting animal body weight. Thus, a more effective agent has 
been developed that can decrease melanoma development by targeting 
key signaling pathways without causing major organ-related toxicity.  
Finally, the last phase of the project, was focused on the effect of COX-2 
deletion in the tumor cells rather than in the tumor microenviroment, 
that has already been studied in the first phase of the project, on 
melanoma development and progression. The analysis was conducted 
both in vitro and in vivo by using CRISPR/Cas9 technology to delete COX-
2 gene in B16/F10 murine melanoma cells (B16/PTGS2Δ). Our results 
show that B16/PTGS2Δ cells had a slower growth rate as compared to 
wild-type B16/F10. Furthermore, we found that down-regulation of 
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COX-2 could inhibit cell migration, invasion and focus formation that are 
the major features of metastatic melanoma.  
Taken together our results prove that COX-2 knockdown can affect 
melanoma growth and progression by reducing the proliferative 
potential of B16/F10 and their migration, invasion and colony formation 
ability. Nonetheless, subcutaneously injection of B16/PTGS2Δ cells in 
mice, slightly inhibited both melanoma growth and CXCL1 plasma levels 
confirming the relevance of the tumor microenvironment in promoting 
the switching of the immune system from anti-tumor to pro-tumor 
activity and viceversa, and finally in determining tumor outcome. 
Collectively, our findings show that COX-2 knockdown in melanoma cells 
is able to inhibit cell proliferation, migration and invasiveness. However, 
our in vivo results demonstrate that COX-2 is relevant but not unique in 
determine the complex network between the microenvironment and 
tumors. Understanding the molecular mechanisms of COX-2 and its 
downstream targets will help to implement stromal targeting strategies 
in clinical practice for future therapeutic approaches. 
For this purpose, we focused our attention on miR-143-3p whose 
deregulation has been reported in various cancer [182, 197-200] but so 
far has not been explored in malignant melanoma. miRNAs represent a 
group of endogenous, small, non-coding RNAs that are currently 
emerging as key post-transcriptional regulators of gene expression, 
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affecting a multitude of biological processes including cell proliferation, 
differentiation, survival and motility [201].  
Therefore, changes in the activity of miRNAs caused by chromosomal 
aberrations, genetic mutations and epigenetic changes, have been 
found in several diseases, including cancer [202]. Furthermore, there 
are also several studies demonstrating the important regulatory role of 
miRNAs during the melanoma progression [203-205]. In our study we 
demonstrate that miR-143-3p expression is downregulated in 
melanoma cell lines as compared to melanocytes suggesting that it 
might function as a tumor suppressor. 
 In addition, ectopic miR-143-3p expression into metastatic melanoma 
cells suppresses proliferation, migration and invasiveness while it 
promotes apoptosis. To explore the mechanism involved in miR-143-3p-
mediated tumor suppression, we searched, and found, a putative 
binding site of miR-143-3p in the 3′UTR of COX-2 gene. The luciferase 
reporter assay determined that the binding site identified was the 
functional site predicted. Indeed, miR-143-3p suppressed the 
transcription activity of COX-2 gene, as well as reduced the expression 
of COX-2 mRNA and protein upon transfection with miR-143-3p mimics. 
Finally, we measured the expression of miR-143-3p within the same 
cluster of human samples analysed during the first phase of the project. 
We found an inverse correlation between miR-143-3p expression and 
COX-2 expression. Indeed, the expression of miR-143-3p is significantly 
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decreased in melanoma specimens (primary melanoma lesions and 
metastases) as compared to human epidermal melanocytes. 
Our results demonstrated that miR-143-3p could function as tumor 
suppressor targeting and repressing COX-2 expression and activity 
suggesting that the miR-143-3p/COX-2 balance is an important factor in 
malignant melanoma tumorigenesis. These data suggest that miR-143-
3p has all the features of a novel diagnostic marker and/or therapeutic 
tool in malignant melanoma. 
In conclusion, all the results collected in these years point toward the 
definition of a prominent role for COX-2 in human melanoma 
progression and open new and exciting perspectives for the therapy of 
this still uncurable disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 129 
 
CHAPTER 6: REFERENCES  
[1] R. Medzhitov, Origin and physiological roles of inflammation, Nature 
454(7203) (2008) 428-35. 
 
[2] I.M. Donaldson, Celsus: De medicina, Florence 1478. Part 1, The journal of the 
Royal College of Physicians of Edinburgh 44(3) (2014) 252-4. 
 
[3] D. Okin, R. Medzhitov, Evolution of inflammatory diseases, Current biology : CB 
22(17) (2012) R733-40. 
 
[4] C. Nathan, Neutrophils and immunity: challenges and opportunities, Nature 
reviews. Immunology 6(3) (2006) 173-82. 
 
[5] M.O. Freire, T.E. Van Dyke, Natural resolution of inflammation, Periodontology 
2000 63(1) (2013) 149-64. 
 
[6] C.E. Broos, M. van Nimwegen, H.C. Hoogsteden, R.W. Hendriks, M. Kool, B. van 
den Blink, Granuloma formation in pulmonary sarcoidosis, Frontiers in 
immunology 4 (2013) 437. 
 
[7] T. Molnar, L. Tiszlavicz, C. Gyulai, F. Nagy, J. Lonovics, Clinical significance of 
granuloma in Crohn's disease, World journal of gastroenterology 11(20) (2005) 
3118-21. 
 
[8] G.T. Williams, W.J. Williams, Granulomatous inflammation--a review, Journal 
of clinical pathology 36(7) (1983) 723-33. 
 
[9] R.H. Straub, C. Schradin, Chronic inflammatory systemic diseases: An 
evolutionary trade-off between acutely beneficial but chronically harmful 
programs, Evolution, medicine, and public health 2016(1) (2016) 37-51. 
 
[10] W. Huang, C.K. Glass, Nuclear receptors and inflammation control: molecular 
mechanisms and pathophysiological relevance, Arteriosclerosis, thrombosis, and 
vascular biology 30(8) (2010) 1542-9. 
 
[11] R. Medzhitov, C.A. Janeway, Jr., Innate immunity: the virtues of a nonclonal 
system of recognition, Cell 91(3) (1997) 295-8. 
 
[12] S. Mariathasan, D.S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-
Girma, W.P. Lee, Y. Weinrauch, D.M. Monack, V.M. Dixit, Cryopyrin activates the 
inflammasome in response to toxins and ATP, Nature 440(7081) (2006) 228-32. 
 
[13] J.S. Park, F. Gamboni-Robertson, Q. He, D. Svetkauskaite, J.Y. Kim, D. 
Strassheim, J.W. Sohn, S. Yamada, I. Maruyama, A. Banerjee, A. Ishizaka, E. 
Abraham, High mobility group box 1 protein interacts with multiple Toll-like 
receptors, American journal of physiology. Cell physiology 290(3) (2006) C917-24. 
 
[14] K.L. Rock, H. Kono, The inflammatory response to cell death, Annual review of 
pathology 3 (2008) 99-126. 
CHAPTER 6 
130 
 
[15] F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, J. Tschopp, Gout-associated uric 
acid crystals activate the NALP3 inflammasome, Nature 440(7081) (2006) 237-41. 
 
[16] O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation, Cell 
140(6) (2010) 805-20. 
 
[17] S. Akira, S. Uematsu, O. Takeuchi, Pathogen recognition and innate immunity, 
Cell 124(4) (2006) 783-801. 
 
[18] T. Kawai, S. Akira, Regulation of innate immune signalling pathways by the 
tripartite motif (TRIM) family proteins, EMBO molecular medicine 3(9) (2011) 513-
27. 
 
[19] T. Okusawa, M. Fujita, J. Nakamura, T. Into, M. Yasuda, A. Yoshimura, Y. Hara, 
A. Hasebe, D.T. Golenbock, M. Morita, Y. Kuroki, T. Ogawa, K. Shibata, 
Relationship between structures and biological activities of mycoplasmal 
diacylated lipopeptides and their recognition by toll-like receptors 2 and 6, 
Infection and immunity 72(3) (2004) 1657-65. 
 
[20] D.M. Agnese, J.E. Calvano, S.J. Hahm, S.M. Coyle, S.A. Corbett, S.E. Calvano, 
S.F. Lowry, Human toll-like receptor 4 mutations but not CD14 polymorphisms are 
associated with an increased risk of gram-negative infections, The Journal of 
infectious diseases 186(10) (2002) 1522-5. 
 
[21] J.C. Bambou, A. Giraud, S. Menard, B. Begue, S. Rakotobe, M. Heyman, F. 
Taddei, N. Cerf-Bensussan, V. Gaboriau-Routhiau, In vitro and ex vivo activation of 
the TLR5 signaling pathway in intestinal epithelial cells by a commensal 
Escherichia coli strain, The Journal of biological chemistry 279(41) (2004) 42984-
92. 
 
[22] K. Takeda, S. Akira, Toll-like receptors in innate immunity, International 
immunology 17(1) (2005) 1-14. 
 
[23] S. Jiang, X. Li, N.J. Hess, Y. Guan, R.I. Tapping, TLR10 Is a Negative Regulator of 
Both MyD88-Dependent and -Independent TLR Signaling, Journal of immunology 
196(9) (2016) 3834-41. 
 
[24] D. Kabelitz, D. Wesch, H.H. Oberg, Regulation of regulatory T cells: role of 
dendritic cells and toll-like receptors, Critical reviews in immunology 26(4) (2006) 
291-306. 
 
[25] J.H. Jang, H.W. Shin, J.M. Lee, H.W. Lee, E.C. Kim, S.H. Park, An Overview of 
Pathogen Recognition Receptors for Innate Immunity in Dental Pulp, Mediators of 
inflammation 2015 (2015) 794143. 
 
[26] A. Broad, J.A. Kirby, D.E. Jones, I. Applied, G. Transplantation Research, Toll-
like receptor interactions: tolerance of MyD88-dependent cytokines but 
enhancement of MyD88-independent interferon-beta production, Immunology 
120(1) (2007) 103-11. 
 
REFERENCES 
131 
 
[27] D. Bamming, C.M. Horvath, Regulation of signal transduction by enzymatically 
inactive antiviral RNA helicase proteins MDA5, RIG-I, and LGP2, The Journal of 
biological chemistry 284(15) (2009) 9700-12. 
 
[28] A. Hartlova, S.F. Erttmann, F.A. Raffi, A.M. Schmalz, U. Resch, S. Anugula, S. 
Lienenklaus, L.M. Nilsson, A. Kroger, J.A. Nilsson, T. Ek, S. Weiss, N.O. Gekara, DNA 
damage primes the type I interferon system via the cytosolic DNA sensor STING to 
promote anti-microbial innate immunity, Immunity 42(2) (2015) 332-343. 
 
[29] K. Li, S. Qu, X. Chen, Q. Wu, M. Shi, Promising Targets for Cancer 
Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways, 
International journal of molecular sciences 18(2) (2017). 
 
[30] T. Kawai, S. Akira, The roles of TLRs, RLRs and NLRs in pathogen recognition, 
International immunology 21(4) (2009) 317-37. 
 
[31] M. Lamkanfi, V.M. Dixit, Mechanisms and functions of inflammasomes, Cell 
157(5) (2014) 1013-22. 
 
[32] C.A. Dinarello, Immunological and inflammatory functions of the interleukin-1 
family, Annual review of immunology 27 (2009) 519-50. 
 
[33] F. Borriello, R. Iannone, G. Marone, Histamine Release from Mast Cells and 
Basophils, Handbook of experimental pharmacology 241 (2017) 121-139. 
 
[34] C. Golias, A. Charalabopoulos, D. Stagikas, K. Charalabopoulos, A. Batistatou, 
The kinin system--bradykinin: biological effects and clinical implications. Multiple 
role of the kinin system--bradykinin, Hippokratia 11(3) (2007) 124-8. 
 
[35] P.J. Haas, J. van Strijp, Anaphylatoxins: their role in bacterial infection and 
inflammation, Immunologic research 37(3) (2007) 161-75. 
 
[36] M. Noris, G. Remuzzi, Overview of complement activation and regulation, 
Seminars in nephrology 33(6) (2013) 479-92. 
 
[37] J.M. Zhang, J. An, Cytokines, inflammation, and pain, International 
anesthesiology clinics 45(2) (2007) 27-37. 
 
[38] P. Proost, A. Wuyts, J. van Damme, The role of chemokines in inflammation, 
International journal of clinical & laboratory research 26(4) (1996) 211-23. 
 
[39] M. Mittal, M.R. Siddiqui, K. Tran, S.P. Reddy, A.B. Malik, Reactive oxygen 
species in inflammation and tissue injury, Antioxidants & redox signaling 20(7) 
(2014) 1126-67. 
 
[40] R. Korhonen, A. Lahti, H. Kankaanranta, E. Moilanen, Nitric oxide production 
and signaling in inflammation, Current drug targets. Inflammation and allergy 4(4) 
(2005) 471-9. 
 
[41] J.N. Sharma, A. Al-Omran, S.S. Parvathy, Role of nitric oxide in inflammatory 
diseases, Inflammopharmacology 15(6) (2007) 252-9. 
CHAPTER 6 
132 
 
[42] L.S. Simon, Role and regulation of cyclooxygenase-2 during inflammation, The 
American journal of medicine 106(5B) (1999) 37S-42S. 
 
[43] L.J. Crofford, COX-1 and COX-2 tissue expression: implications and 
predictions, The Journal of rheumatology. Supplement 49 (1997) 15-9. 
 
[44] Y.S. Bakhle, R.M. Botting, Cyclooxygenase-2 and its regulation in 
inflammation, Mediators of inflammation 5(5) (1996) 305-23. 
 
[45] T. Kosaka, A. Miyata, H. Ihara, S. Hara, T. Sugimoto, O. Takeda, E. Takahashi, 
T. Tanabe, Characterization of the human gene (PTGS2) encoding prostaglandin-
endoperoxide synthase 2, European journal of biochemistry 221(3) (1994) 889-97. 
 
[46] F.G. Smith, A.W. Wade, M.L. Lewis, W. Qi, Cyclooxygenase (COX) Inhibitors 
and the Newborn Kidney, Pharmaceuticals 5(11) (2012) 1160-76. 
 
[47] J.M. Wright, The double-edged sword of COX-2 selective NSAIDs, CMAJ : 
Canadian Medical Association journal = journal de l'Association medicale 
canadienne 167(10) (2002) 1131-7. 
 
[48] D.L. Simmons, R.M. Botting, T. Hla, Cyclooxygenase isozymes: the biology of 
prostaglandin synthesis and inhibition, Pharmacological reviews 56(3) (2004) 387-
437. 
 
[49] B. Grygiel-Gorniak, Peroxisome proliferator-activated receptors and their 
ligands: nutritional and clinical implications--a review, Nutrition journal 13 (2014) 
17. 
 
[50] D. Wang, R.N. Dubois, Eicosanoids and cancer, Nature reviews. Cancer 10(3) 
(2010) 181-93. 
 
[51] D. Wang, R.N. DuBois, Measurement of eicosanoids in cancer tissues, 
Methods in enzymology 433 (2007) 27-50. 
 
[52] F. Balkwill, A. Mantovani, Inflammation and cancer: back to Virchow?, Lancet 
357(9255) (2001) 539-45. 
 
[53] D. Hanahan, R.A. Weinberg, Hallmarks of cancer: the next generation, Cell 
144(5) (2011) 646-74. 
 
[54] S. Agarwal, G.V. Reddy, P. Reddanna, Eicosanoids in inflammation and cancer: 
the role of COX-2, Expert review of clinical immunology 5(2) (2009) 145-65. 
 
[55] A. Mantovani, Cancer: inflammation by remote control, Nature 435(7043) 
(2005) 752-3. 
 
[56] Y.R. Mahida, The key role of macrophages in the immunopathogenesis of 
inflammatory bowel disease, Inflammatory bowel diseases 6(1) (2000) 21-33. 
 
[57] D. Wang, R.N. Dubois, The role of COX-2 in intestinal inflammation and 
colorectal cancer, Oncogene 29(6) (2010) 781-8. 
REFERENCES 
133 
 
[58] L.R. Howe, Inflammation and breast cancer. Cyclooxygenase/prostaglandin 
signaling and breast cancer, Breast cancer research : BCR 9(4) (2007) 210. 
 
[59] R.S. Bresalier, R.S. Sandler, H. Quan, J.A. Bolognese, B. Oxenius, K. Horgan, C. 
Lines, R. Riddell, D. Morton, A. Lanas, M.A. Konstam, J.A. Baron, I. Adenomatous 
Polyp Prevention on Vioxx Trial, Cardiovascular events associated with rofecoxib 
in a colorectal adenoma chemoprevention trial, The New England journal of 
medicine 352(11) (2005) 1092-102. 
 
[60] S.D. Solomon, J.J. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, P. Finn, W.F. 
Anderson, A. Zauber, E. Hawk, M. Bertagnolli, I. Adenoma Prevention with 
Celecoxib Study, Cardiovascular risk associated with celecoxib in a clinical trial for 
colorectal adenoma prevention, The New England journal of medicine 352(11) 
(2005) 1071-80. 
 
[61] J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan, R. Riddell, A. Lanas, J.A. 
Bolognese, B. Oxenius, K. Horgan, S. Loftus, D.G. Morton, A.P.T. Investigators, A 
randomized trial of rofecoxib for the chemoprevention of colorectal adenomas, 
Gastroenterology 131(6) (2006) 1674-82. 
 
[62] T.L. McLemore, W.C. Hubbard, C.L. Litterst, M.C. Liu, S. Miller, N.A. 
McMahon, J.C. Eggleston, M.R. Boyd, Profiles of prostaglandin biosynthesis in 
normal lung and tumor tissue from lung cancer patients, Cancer research 48(11) 
(1988) 3140-7. 
 
[63] M. Hambek, M. Baghi, J. Wagenblast, J. Schmitt, H. Baumann, R. Knecht, 
Inverse correlation between serum PGE2 and T classification in head and neck 
cancer, Head & neck 29(3) (2007) 244-8. 
 
[64] G. Hawcroft, M. Volpato, G. Marston, N. Ingram, S.L. Perry, A.J. Cockbain, A.D. 
Race, A. Munarini, A. Belluzzi, P.M. Loadman, P.L. Coletta, M.A. Hull, The omega-3 
polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal 
cancer cell liver metastasis via inhibition of PGE2-dependent cell motility, British 
journal of pharmacology 166(5) (2012) 1724-37. 
 
[65] C.A. Dinarello, The paradox of pro-inflammatory cytokines in cancer, Cancer 
metastasis reviews 25(3) (2006) 307-13. 
 
[66] W. Walker, D. Rotondo, Prostaglandin E2 is a potent regulator of interleukin-
12- and interleukin-18-induced natural killer cell interferon-gamma synthesis, 
Immunology 111(3) (2004) 298-305. 
 
[67] P. Sinha, V.K. Clements, A.M. Fulton, S. Ostrand-Rosenberg, Prostaglandin E2 
promotes tumor progression by inducing myeloid-derived suppressor cells, Cancer 
research 67(9) (2007) 4507-13. 
 
[68] M.G. Backlund, J.R. Mann, V.R. Holla, F.G. Buchanan, H.H. Tai, E.S. Musiek, 
G.L. Milne, S. Katkuri, R.N. DuBois, 15-Hydroxyprostaglandin dehydrogenase is 
down-regulated in colorectal cancer, The Journal of biological chemistry 280(5) 
(2005) 3217-23. 
CHAPTER 6 
134 
 
[69] I. Wolf, J. O'Kelly, T. Rubinek, M. Tong, A. Nguyen, B.T. Lin, H.H. Tai, B.Y. 
Karlan, H.P. Koeffler, 15-hydroxyprostaglandin dehydrogenase is a tumor 
suppressor of human breast cancer, Cancer research 66(15) (2006) 7818-23. 
 
[70] A. Thiel, A. Ganesan, J. Mrena, S. Junnila, A. Nykanen, A. Hemmes, H.H. Tai, O. 
Monni, A. Kokkola, C. Haglund, T.V. Petrova, A. Ristimaki, 15-
hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer, Clinical 
cancer research : an official journal of the American Association for Cancer 
Research 15(14) (2009) 4572-80. 
 
[71] S. Tseng-Rogenski, J. Gee, K.W. Ignatoski, L.P. Kunju, A. Bucheit, H.J. Kintner, 
D. Morris, C. Tallman, J. Evron, C.G. Wood, H.B. Grossman, C.T. Lee, M. Liebert, 
Loss of 15-hydroxyprostaglandin dehydrogenase expression contributes to 
bladder cancer progression, The American journal of pathology 176(3) (2010) 
1462-8. 
 
[72] K. Watanabe, T. Kawamori, S. Nakatsugi, T. Ohta, S. Ohuchida, H. Yamamoto, 
T. Maruyama, K. Kondo, F. Ushikubi, S. Narumiya, T. Sugimura, K. Wakabayashi, 
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis, Cancer 
research 59(20) (1999) 5093-6. 
 
[73] Y. Shoji, M. Takahashi, N. Takasuka, N. Niho, T. Kitamura, H. Sato, T. 
Maruyama, Y. Sugimoto, S. Narumiya, T. Sugimura, K. Wakabayashi, Prostaglandin 
E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin 
carcinogenesis, Carcinogenesis 26(12) (2005) 2116-22. 
 
[74] M. Mutoh, K. Watanabe, T. Kitamura, Y. Shoji, M. Takahashi, T. Kawamori, K. 
Tani, M. Kobayashi, T. Maruyama, K. Kobayashi, S. Ohuchida, Y. Sugimoto, S. 
Narumiya, T. Sugimura, K. Wakabayashi, Involvement of prostaglandin E receptor 
subtype EP(4) in colon carcinogenesis, Cancer research 62(1) (2002) 28-32. 
 
[75] T. Kawamori, N. Uchiya, S. Nakatsugi, K. Watanabe, S. Ohuchida, H. 
Yamamoto, T. Maruyama, K. Kondo, T. Sugimura, K. Wakabayashi, 
Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) 
antagonist, on breast cancer development, Carcinogenesis 22(12) (2001) 2001-4. 
 
[76] J.M. Park, Y. Kanaoka, N. Eguchi, K. Aritake, S. Grujic, A.M. Materi, V.S. 
Buslon, B.L. Tippin, A.M. Kwong, E. Salido, S.W. French, Y. Urade, H.J. Lin, 
Hematopoietic prostaglandin D synthase suppresses intestinal adenomas in 
ApcMin/+ mice, Cancer research 67(3) (2007) 881-9. 
 
[77] S. Trabanelli, M.F. Chevalier, A. Martinez-Usatorre, A. Gomez-Cadena, B. 
Salome, M. Lecciso, V. Salvestrini, G. Verdeil, J. Racle, C. Papayannidis, H. Morita, 
I. Pizzitola, C. Grandclement, P. Bohner, E. Bruni, M. Girotra, R. Pallavi, P. Falvo, 
E.O. Leibundgut, G.M. Baerlocher, C. Carlo-Stella, D. Taurino, A. Santoro, O. 
Spinelli, A. Rambaldi, E. Giarin, G. Basso, C. Tresoldi, F. Ciceri, D. Gfeller, C.A. 
Akdis, L. Mazzarella, S. Minucci, P.G. Pelicci, E. Marcenaro, A.N.J. McKenzie, D. 
Vanhecke, G. Coukos, D. Mavilio, A. Curti, L. Derre, C. Jandus, Tumour-derived 
PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC 
axis, Nature communications 8(1) (2017) 593. 
REFERENCES 
135 
 
[78] G.P. Pidgeon, J. Lysaght, S. Krishnamoorthy, J.V. Reynolds, K. O'Byrne, D. Nie, 
K.V. Honn, Lipoxygenase metabolism: roles in tumor progression and survival, 
Cancer metastasis reviews 26(3-4) (2007) 503-24. 
 
[79] P.C. Ho, K.M. Meeth, Y.C. Tsui, B. Srivastava, M.W. Bosenberg, S.M. Kaech, 
Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L 
and IFNgamma, Cancer research 74(12) (2014) 3205-17. 
 
[80] V. Samarasinghe, V. Madan, Nonmelanoma skin cancer, Journal of cutaneous 
and aesthetic surgery 5(1) (2012) 3-10. 
 
[81] S. Garcovich, G. Colloca, P. Sollena, B. Andrea, L. Balducci, W.C. Cho, R. 
Bernabei, K. Peris, Skin Cancer Epidemics in the Elderly as An Emerging Issue in 
Geriatric Oncology, Aging and disease 8(5) (2017) 643-661. 
 
[82] Y. Cheng, J. Lu, G. Chen, G.S. Ardekani, A. Rotte, M. Martinka, X. Xu, K.J. 
McElwee, G. Zhang, Y. Zhou, Stage-specific prognostic biomarkers in melanoma, 
Oncotarget 6(6) (2015) 4180-9. 
 
[83] N.H. Matthews, W.Q. Li, A.A. Qureshi, M.A. Weinstock, E. Cho, Epidemiology 
of Melanoma, in: W.H. Ward, J.M. Farma (Eds.), Cutaneous Melanoma: Etiology 
and Therapy, Brisbane (AU), 2017. 
 
[84] J. Moan, M. Grigalavicius, Z. Baturaite, A. Dahlback, A. Juzeniene, The 
relationship between UV exposure and incidence of skin cancer, 
Photodermatology, photoimmunology & photomedicine 31(1) (2015) 26-35. 
 
[85] M. Piepkorn, Melanoma genetics: an update with focus on the 
CDKN2A(p16)/ARF tumor suppressors, Journal of the American Academy of 
Dermatology 42(5 Pt 1) (2000) 705-22; quiz 723-6. 
 
[86] Z. Ji, K.T. Flaherty, H. Tsao, Targeting the RAS pathway in melanoma, Trends 
in molecular medicine 18(1) (2012) 27-35. 
 
[87] P.A. Ascierto, J.M. Kirkwood, J.J. Grob, E. Simeone, A.M. Grimaldi, M. Maio, G. 
Palmieri, A. Testori, F.M. Marincola, N. Mozzillo, The role of BRAF V600 mutation 
in melanoma, Journal of translational medicine 10 (2012) 85. 
 
[88] V.C. Gorantla, J.M. Kirkwood, State of melanoma: an historic overview of a 
field in transition, Hematology/oncology clinics of North America 28(3) (2014) 
415-35. 
 
[89] D.D. Sarbassov, D.A. Guertin, S.M. Ali, D.M. Sabatini, Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex, Science 307(5712) (2005) 
1098-101. 
 
[90] V. Gray-Schopfer, C. Wellbrock, R. Marais, Melanoma biology and new 
targeted therapy, Nature 445(7130) (2007) 851-7. 
 
[91] C. Perlis, M. Herlyn, Recent advances in melanoma biology, The oncologist 
9(2) (2004) 182-7. 
CHAPTER 6 
136 
 
[92] A.J. Miller, M.C. Mihm, Jr., Melanoma, The New England journal of medicine 
355(1) (2006) 51-65. 
 
[93] W.H. Clark, Tumour progression and the nature of cancer, British journal of 
cancer 64(4) (1991) 631-44. 
 
[94] P.V. Dickson, J.E. Gershenwald, Staging and prognosis of cutaneous 
melanoma, Surgical oncology clinics of North America 20(1) (2011) 1-17. 
 
[95] L.J. Titus, K. Clough-Gorr, T.A. Mackenzie, A. Perry, S.K. Spencer, J. Weiss, S. 
Abrahams-Gessel, M.S. Ernstoff, Recent skin self-examination and doctor visits in 
relation to melanoma risk and tumour depth, The British journal of dermatology 
168(3) (2013) 571-6. 
 
[96] M.C. Mihm, Jr., J.J. Mule, Reflections on the Histopathology of Tumor-
Infiltrating Lymphocytes in Melanoma and the Host Immune Response, Cancer 
immunology research 3(8) (2015) 827-35. 
 
[97] W.H. Clark, Jr., D.E. Elder, D.t. Guerry, L.E. Braitman, B.J. Trock, D. Schultz, M. 
Synnestvedt, A.C. Halpern, Model predicting survival in stage I melanoma based 
on tumor progression, Journal of the National Cancer Institute 81(24) (1989) 
1893-904. 
 
[98] M.G. Hansen, A.B. McCarten, Tumor thickness and lymphocytic infiltration in 
malignant melanoma of the head and neck, American journal of surgery 128(4) 
(1974) 557-61. 
 
[99] R.C. Taylor, A. Patel, K.S. Panageas, K.J. Busam, M.S. Brady, Tumor-infiltrating 
lymphocytes predict sentinel lymph node positivity in patients with cutaneous 
melanoma, Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 25(7) (2007) 869-75. 
 
[100] A.L. Burton, B.A. Roach, M.P. Mays, A.F. Chen, B.A. Ginter, A.M. Vierling, C.R. 
Scoggins, R.C. Martin, A.J. Stromberg, L. Hagendoorn, K.M. McMasters, Prognostic 
significance of tumor infiltrating lymphocytes in melanoma, The American 
surgeon 77(2) (2011) 188-92. 
 
[101] T. Schatton, R.A. Scolyer, J.F. Thompson, M.C. Mihm, Jr., Tumor-infiltrating 
lymphocytes and their significance in melanoma prognosis, Methods in molecular 
biology 1102 (2014) 287-324. 
 
[102] D.A. Oble, R. Loewe, P. Yu, M.C. Mihm, Jr., Focus on TILs: prognostic 
significance of tumor infiltrating lymphocytes in human melanoma, Cancer 
immunity 9 (2009) 3. 
 
[103] F. Piras, R. Colombari, L. Minerba, D. Murtas, C. Floris, C. Maxia, A. Corbu, 
M.T. Perra, P. Sirigu, The predictive value of CD8, CD4, CD68, and human 
leukocyte antigen-D-related cells in the prognosis of cutaneous malignant 
melanoma with vertical growth phase, Cancer 104(6) (2005) 1246-54. 
 
REFERENCES 
137 
 
[104] C. Yee, P. Greenberg, Modulating T-cell immunity to tumours: new 
strategies for monitoring T-cell responses, Nature reviews. Cancer 2(6) (2002) 
409-19. 
 
[105] D.E. Gyorki, M. Callahan, J.D. Wolchok, C.E. Ariyan, The delicate balance of 
melanoma immunotherapy, Clinical & translational immunology 2(8) (2013) e5. 
 
[106] M.J. Pittet, D.E. Speiser, D. Valmori, D. Rimoldi, D. Lienard, F. Lejeune, J.C. 
Cerottini, P. Romero, Ex vivo analysis of tumor antigen specific CD8+ T cell 
responses using MHC/peptide tetramers in cancer patients, International 
immunopharmacology 1(7) (2001) 1235-47. 
 
[107] P. Romero, D. Valmori, M.J. Pittet, A. Zippelius, D. Rimoldi, F. Levy, V. Dutoit, 
M. Ayyoub, V. Rubio-Godoy, O. Michielin, P. Guillaume, P. Batard, I.F. Luescher, F. 
Lejeune, D. Lienard, N. Rufer, P.Y. Dietrich, D.E. Speiser, J.C. Cerottini, Antigenicity 
and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor 
reactive CTL in human melanoma, Immunological reviews 188 (2002) 81-96. 
 
[108] P.F. Robbins, M. El-Gamil, Y.F. Li, G. Zeng, M. Dudley, S.A. Rosenberg, 
Multiple HLA class II-restricted melanocyte differentiation antigens are recognized 
by tumor-infiltrating lymphocytes from a patient with melanoma, Journal of 
immunology 169(10) (2002) 6036-47. 
 
[109] T. Boon, P.G. Coulie, B.J. Van den Eynde, P. van der Bruggen, Human T cell 
responses against melanoma, Annual review of immunology 24 (2006) 175-208. 
 
[110] B.M. Olson, D.G. McNeel, Antigen loss and tumor-mediated 
immunosuppression facilitate tumor recurrence, Expert review of vaccines 11(11) 
(2012) 1315-7. 
 
[111] V. Bronte, T. Kasic, G. Gri, K. Gallana, G. Borsellino, I. Marigo, L. Battistini, M. 
Iafrate, T. Prayer-Galetti, F. Pagano, A. Viola, Boosting antitumor responses of T 
lymphocytes infiltrating human prostate cancers, The Journal of experimental 
medicine 201(8) (2005) 1257-68. 
 
[112] S. Lang, A. Picu, T. Hofmann, M. Andratschke, B. Mack, A. Moosmann, O. 
Gires, S. Tiwari, R. Zeidler, COX-inhibitors relieve the immunosuppressive effect of 
tumor cells and improve functions of immune effectors, International journal of 
immunopathology and pharmacology 19(2) (2006) 409-19. 
 
[113] B.F. Zamarron, W. Chen, Dual roles of immune cells and their factors in 
cancer development and progression, International journal of biological sciences 
7(5) (2011) 651-8. 
 
[114] M. Munder, H. Schneider, C. Luckner, T. Giese, C.D. Langhans, J.M. Fuentes, 
P. Kropf, I. Mueller, A. Kolb, M. Modolell, A.D. Ho, Suppression of T-cell functions 
by human granulocyte arginase, Blood 108(5) (2006) 1627-34. 
 
[115] D.I. Gabrilovich, S. Nagaraj, Myeloid-derived suppressor cells as regulators 
of the immune system, Nature reviews. Immunology 9(3) (2009) 162-74. 
CHAPTER 6 
138 
 
[116] B. Shang, Y. Liu, S.J. Jiang, Y. Liu, Prognostic value of tumor-infiltrating 
FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis, 
Scientific reports 5 (2015) 15179. 
 
[117] S. Spranger, R.M. Spaapen, Y. Zha, J. Williams, Y. Meng, T.T. Ha, T.F. 
Gajewski, Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor 
microenvironment is driven by CD8(+) T cells, Science translational medicine 
5(200) (2013) 200ra116. 
 
[118] P. Strojan, Role of radiotherapy in melanoma management, Radiology and 
oncology 44(1) (2010) 1-12. 
 
[119] M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, K. Margolin, J. 
Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, S.A. 
Rosenberg, High-dose recombinant interleukin 2 therapy for patients with 
metastatic melanoma: analysis of 270 patients treated between 1985 and 1993, 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 17(7) (1999) 2105-16. 
 
[120] P.B. Chapman, A. Hauschild, C. Robert, J.B. Haanen, P. Ascierto, J. Larkin, R. 
Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. 
Schadendorf, A. Ribas, S.J. O'Day, J.A. Sosman, J.M. Kirkwood, A.M. Eggermont, B. 
Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R.J. Lee, K.T. Flaherty, G.A. McArthur, B.-S. 
Group, Improved survival with vemurafenib in melanoma with BRAF V600E 
mutation, The New England journal of medicine 364(26) (2011) 2507-16. 
 
[121] J. Villanueva, A. Vultur, M. Herlyn, Resistance to BRAF inhibitors: unraveling 
mechanisms and future treatment options, Cancer research 71(23) (2011) 7137-
40. 
 
[122] A. Ribas, R. Kefford, M.A. Marshall, C.J. Punt, J.B. Haanen, M. Marmol, C. 
Garbe, H. Gogas, J. Schachter, G. Linette, P. Lorigan, K.L. Kendra, M. Maio, U. 
Trefzer, M. Smylie, G.A. McArthur, B. Dreno, P.D. Nathan, J. Mackiewicz, J.M. 
Kirkwood, J. Gomez-Navarro, B. Huang, D. Pavlov, A. Hauschild, Phase III 
randomized clinical trial comparing tremelimumab with standard-of-care 
chemotherapy in patients with advanced melanoma, Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 31(5) (2013) 616-22. 
 
[123] G. Tosti, E. Cocorocchio, E. Pennacchioli, Anti-cytotoxic T lymphocyte 
antigen-4 antibodies in melanoma, Clinical, cosmetic and investigational 
dermatology 6 (2013) 245-56. 
 
[124] T.R. Simpson, F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. 
Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, K.S. Peggs, J.V. Ravetch, J.P. 
Allison, S.A. Quezada, Fc-dependent depletion of tumor-infiltrating regulatory T 
cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma, The Journal 
of experimental medicine 210(9) (2013) 1695-710. 
 
[125] J.D. Wolchok, B. Neyns, G. Linette, S. Negrier, J. Lutzky, L. Thomas, W. 
Waterfield, D. Schadendorf, M. Smylie, T. Guthrie, Jr., J.J. Grob, J. Chesney, K. 
Chin, K. Chen, A. Hoos, S.J. O'Day, C. Lebbe, Ipilimumab monotherapy in patients 
REFERENCES 
139 
 
with pretreated advanced melanoma: a randomised, double-blind, multicentre, 
phase 2, dose-ranging study, The Lancet. Oncology 11(2) (2010) 155-64. 
 
[126] C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbe, 
J.F. Baurain, A. Testori, J.J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, 
W.H. Miller, Jr., P. Gascon, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, T.T. 
Chen, R. Humphrey, A. Hoos, J.D. Wolchok, Ipilimumab plus dacarbazine for 
previously untreated metastatic melanoma, The New England journal of medicine 
364(26) (2011) 2517-26. 
 
[127] D.B. Johnson, C. Peng, J.A. Sosman, Nivolumab in melanoma: latest evidence 
and clinical potential, Therapeutic advances in medical oncology 7(2) (2015) 97-
106. 
 
[128] O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, 
P. Hersey, R.W. Joseph, J.S. Weber, R. Dronca, T.C. Gangadhar, A. Patnaik, H. 
Zarour, A.M. Joshua, K. Gergich, J. Elassaiss-Schaap, A. Algazi, C. Mateus, P. 
Boasberg, P.C. Tumeh, B. Chmielowski, S.W. Ebbinghaus, X.N. Li, S.P. Kang, A. 
Ribas, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, 
The New England journal of medicine 369(2) (2013) 134-44. 
 
[129] C. Jandus, D. Speiser, P. Romero, Recent advances and hurdles in melanoma 
immunotherapy, Pigment cell & melanoma research 22(6) (2009) 711-23. 
 
[130] M.J. Besser, R. Shapira-Frommer, O. Itzhaki, A.J. Treves, D.B. Zippel, D. Levy, 
A. Kubi, N. Shoshani, D. Zikich, Y. Ohayon, D. Ohayon, B. Shalmon, G. Markel, R. 
Yerushalmi, S. Apter, A. Ben-Nun, E. Ben-Ami, A. Shimoni, A. Nagler, J. Schachter, 
Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic 
melanoma: intent-to-treat analysis and efficacy after failure to prior 
immunotherapies, Clinical cancer research : an official journal of the American 
Association for Cancer Research 19(17) (2013) 4792-800. 
 
[131] R. Perret, S.R. Sierro, N.K. Botelho, S. Corgnac, A. Donda, P. Romero, 
Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells 
enhance tumor immunity, Cancer research 73(22) (2013) 6597-608. 
 
[132] L. Baitsch, P. Baumgaertner, E. Devevre, S.K. Raghav, A. Legat, L. Barba, S. 
Wieckowski, H. Bouzourene, B. Deplancke, P. Romero, N. Rufer, D.E. Speiser, 
Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma 
patients, The Journal of clinical investigation 121(6) (2011) 2350-60. 
 
[133] Y. Fan, R. Mao, J. Yang, NF-kappaB and STAT3 signaling pathways 
collaboratively link inflammation to cancer, Protein & cell 4(3) (2013) 176-85. 
 
[134] M.K. Shanmugam, A.H. Nguyen, A.P. Kumar, B.K. Tan, G. Sethi, Targeted 
inhibition of tumor proliferation, survival, and metastasis by pentacyclic 
triterpenoids: potential role in prevention and therapy of cancer, Cancer letters 
320(2) (2012) 158-70. 
 
[135] H. Yu, M. Kortylewski, D. Pardoll, Crosstalk between cancer and immune 
cells: role of STAT3 in the tumour microenvironment, Nature reviews. 
Immunology 7(1) (2007) 41-51. 
CHAPTER 6 
140 
 
[136] H. Haghnegahdar, J. Du, D. Wang, R.M. Strieter, M.D. Burdick, L.B. Nanney, 
N. Cardwell, J. Luan, R. Shattuck-Brandt, A. Richmond, The tumorigenic and 
angiogenic effects of MGSA/GRO proteins in melanoma, Journal of leukocyte 
biology 67(1) (2000) 53-62. 
 
[137] M. Vougioukalaki, D.C. Kanellis, K. Gkouskou, A.G. Eliopoulos, Tpl2 kinase 
signal transduction in inflammation and cancer, Cancer letters 304(2) (2011) 80-9. 
 
[138] J.H. Chung, S.H. Youn, W.S. Koh, H.C. Eun, K.H. Cho, K.C. Park, J.I. Youn, 
Ultraviolet B irradiation-enhanced interleukin (IL)-6 production and mRNA 
expression are mediated by IL-1 alpha in cultured human keratinocytes, The 
Journal of investigative dermatology 106(4) (1996) 715-20. 
 
[139] S.H. Jee, C.Y. Chu, H.C. Chiu, Y.L. Huang, W.L. Tsai, Y.H. Liao, M.L. Kuo, 
Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in 
basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways, The 
Journal of investigative dermatology 123(6) (2004) 1169-75. 
 
[140] J.E. Rundhaug, S.M. Fischer, Molecular mechanisms of mouse skin tumor 
promotion, Cancers 2(2) (2010) 436-82. 
 
[141] C.Y. Perrot, D. Javelaud, A. Mauviel, Insights into the Transforming Growth 
Factor-beta Signaling Pathway in Cutaneous Melanoma, Annals of dermatology 
25(2) (2013) 135-44. 
 
[142] R.N. Apte, Y. Krelin, X. Song, S. Dotan, E. Recih, M. Elkabets, Y. Carmi, T. 
Dvorkin, R.M. White, L. Gayvoronsky, S. Segal, E. Voronov, Effects of micro-
environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour 
invasiveness and tumour-host interactions, European journal of cancer 42(6) 
(2006) 751-9. 
 
[143] K. Muller-Decker, G. Neufang, I. Berger, M. Neumann, F. Marks, G. 
Furstenberger, Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin 
for carcinogenesis, Proceedings of the National Academy of Sciences of the United 
States of America 99(19) (2002) 12483-8. 
 
[144] H.F. Tiano, C.D. Loftin, J. Akunda, C.A. Lee, J. Spalding, A. Sessoms, D.B. 
Dunson, E.G. Rogan, S.G. Morham, R.C. Smart, R. Langenbach, Deficiency of either 
cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces 
mouse skin tumorigenesis, Cancer research 62(12) (2002) 3395-401. 
 
[145] G. Furstenberger, M. Gross, F. Marks, Eicosanoids and multistage 
carcinogenesis in NMRI mouse skin: role of prostaglandins E and F in conversion 
(first stage of tumor promotion) and promotion (second stage of tumor 
promotion), Carcinogenesis 10(1) (1989) 91-6. 
 
[146] T. Singh, S.K. Katiyar, Green tea catechins reduce invasive potential of 
human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-
mesenchymal transition, PloS one 6(10) (2011) e25224. 
 
[147] K.L. Tober, T.A. Wilgus, D.F. Kusewitt, J.M. Thomas-Ahner, T. Maruyama, 
T.M. Oberyszyn, Importance of the EP(1) receptor in cutaneous UVB-induced 
REFERENCES 
141 
 
inflammation and tumor development, The Journal of investigative dermatology 
126(1) (2006) 205-11. 
 
[148] O. Millan, D. Rico, H. Peinado, N. Zarich, K. Stamatakis, D. Perez-Sala, J.M. 
Rojas, A. Cano, L. Bosca, Potentiation of tumor formation by topical 
administration of 15-deoxy-delta12,14-prostaglandin J2 in a model of skin 
carcinogenesis, Carcinogenesis 27(2) (2006) 328-36. 
 
[149] C. Cahlin, J. Gelin, D. Delbro, C. Lonnroth, C. Doi, K. Lundholm, Effect of 
cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse 
tumor models with and without cancer cachexia related to prostanoids, Cancer 
research 60(6) (2000) 1742-9. 
 
[150] C. Denkert, M. Kobel, S. Berger, A. Siegert, A. Leclere, U. Trefzer, S. 
Hauptmann, Expression of cyclooxygenase 2 in human malignant melanoma, 
Cancer research 61(1) (2001) 303-8. 
 
[151] M.R. Becker, M.D. Siegelin, R. Rompel, A.H. Enk, T. Gaiser, COX-2 expression 
in malignant melanoma: a novel prognostic marker?, Melanoma research 19(1) 
(2009) 8-16. 
 
[152] B.W. Chwirot, L. Kuzbicki, Cyclooxygenase-2 (COX-2): first 
immunohistochemical marker distinguishing early cutaneous melanomas from 
benign melanocytic skin tumours, Melanoma research 17(3) (2007) 139-45. 
 
[153] L. Kuzbicki, A. Sarnecka, B.W. Chwirot, Expression of cyclooxygenase-2 in 
benign naevi and during human cutaneous melanoma progression, Melanoma 
research 16(1) (2006) 29-36. 
 
[154] J. Todoric, L. Antonucci, M. Karin, Targeting Inflammation in Cancer 
Prevention and Therapy, Cancer prevention research 9(12) (2016) 895-905. 
 
[155] M. Fabbri, MicroRNAs and cancer: towards a personalized medicine, Current 
molecular medicine 13(5) (2013) 751-6. 
 
[156] R.J. Gonzalez-Duarte, V. Cazares-Ordonez, E. Avila-Chavez, The microRNA 
biogenesis machinery: regulation by steroid hormones and alterations in cancer, 
Revista de investigacion clinica; organo del Hospital de Enfermedades de la 
Nutricion 66(5) (2014) 460-4. 
 
[157] M.J. Ochs, D. Steinhilber, B. Suess, MicroRNAs-novel therapeutic targets of 
eicosanoid signalling, Basic & clinical pharmacology & toxicology 114(1) (2014) 92-
6. 
 
[158] C. Kilkenny, W. Browne, I.C. Cuthill, M. Emerson, D.G. Altman, N.C.R.R.G.W. 
Group, Animal research: reporting in vivo experiments: the ARRIVE guidelines, 
British journal of pharmacology 160(7) (2010) 1577-9. 
 
[159] B. Ahmetaj-Shala, N.S. Kirkby, R. Knowles, M. Al'Yamani, S. Mazi, Z. Wang, 
A.T. Tucker, L.S. Mackenzie, P.C. Armstrong, R.M. Nusing, J.A. Tomlinson, T.D. 
Warner, J. Leiper, J.A. Mitchell, Reply to letter regarding article, "evidence that 
links loss of cyclooxygenase-2 with increased asymmetric dimethylarginine: novel 
CHAPTER 6 
142 
 
explanation of cardiovascular side effects associated with anti-inflammatory 
drugs", Circulation 132(17) (2015) e213-4. 
 
[160] J. Berkelhammer, R.W. Oxenhandler, R.R. Hook, Jr., J.M. Hennessy, 
Development of a new melanoma model in C57BL/6 mice, Cancer research 42(8) 
(1982) 3157-63. 
 
[161] J.L. Wallace, R. Wang, Hydrogen sulfide-based therapeutics: exploiting a 
unique but ubiquitous gasotransmitter, Nature reviews. Drug discovery 14(5) 
(2015) 329-45. 
 
[162] M.V. Chan, J.L. Wallace, Hydrogen sulfide-based therapeutics and 
gastrointestinal diseases: translating physiology to treatments, American journal 
of physiology. Gastrointestinal and liver physiology 305(7) (2013) G467-73. 
 
[163] E. Panza, P. De Cicco, C. Armogida, G. Scognamiglio, V. Gigantino, G. Botti, D. 
Germano, M. Napolitano, A. Papapetropoulos, M. Bucci, G. Cirino, A. Ianaro, Role 
of the cystathionine gamma lyase/hydrogen sulfide pathway in human melanoma 
progression, Pigment cell & melanoma research 28(1) (2015) 61-72. 
 
[164] Z.W. Lee, J. Zhou, C.S. Chen, Y. Zhao, C.H. Tan, L. Li, P.K. Moore, L.W. Deng, 
The slow-releasing hydrogen sulfide donor, GYY4137, exhibits novel anti-cancer 
effects in vitro and in vivo, PloS one 6(6) (2011) e21077. 
 
[165] M. Chattopadhyay, R. Kodela, N. Nath, A. Barsegian, D. Boring, K. Kashfi, 
Hydrogen sulfide-releasing aspirin suppresses NF-kappaB signaling in estrogen 
receptor negative breast cancer cells in vitro and in vivo, Biochemical 
pharmacology 83(6) (2012) 723-32. 
 
[166] J.L. Wallace, Hydrogen sulfide-releasing anti-inflammatory drugs, Trends in 
pharmacological sciences 28(10) (2007) 501-5. 
 
[167] J.L. Wallace, G. Caliendo, V. Santagada, G. Cirino, Markedly reduced toxicity 
of a hydrogen sulphide-releasing derivative of naproxen (ATB-346), British journal 
of pharmacology 159(6) (2010) 1236-46. 
 
[168] Y. Ueda, A. Richmond, NF-kappaB activation in melanoma, Pigment cell 
research 19(2) (2006) 112-24. 
 
[169] E. Hodis, I.R. Watson, G.V. Kryukov, S.T. Arold, M. Imielinski, J.P. Theurillat, 
E. Nickerson, D. Auclair, L. Li, C. Place, D. Dicara, A.H. Ramos, M.S. Lawrence, K. 
Cibulskis, A. Sivachenko, D. Voet, G. Saksena, N. Stransky, R.C. Onofrio, W. 
Winckler, K. Ardlie, N. Wagle, J. Wargo, K. Chong, D.L. Morton, K. Stemke-Hale, G. 
Chen, M. Noble, M. Meyerson, J.E. Ladbury, M.A. Davies, J.E. Gershenwald, S.N. 
Wagner, D.S. Hoon, D. Schadendorf, E.S. Lander, S.B. Gabriel, G. Getz, L.A. 
Garraway, L. Chin, A landscape of driver mutations in melanoma, Cell 150(2) 
(2012) 251-63. 
 
[170] K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, O. 
Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H.A. Burris, 3rd, G. 
Falchook, A. Algazi, K. Lewis, G.V. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, 
P. Sun, A. Allred, D. Ouellet, K.B. Kim, K. Patel, J. Weber, Combined BRAF and MEK 
REFERENCES 
143 
 
inhibition in melanoma with BRAF V600 mutations, The New England journal of 
medicine 367(18) (2012) 1694-703. 
 
[171] D. Koul, Y. Yao, J.L. Abbruzzese, W.K. Yung, S.A. Reddy, Tumor suppressor 
MMAC/PTEN inhibits cytokine-induced NFkappaB activation without interfering 
with the IkappaB degradation pathway, The Journal of biological chemistry 
276(14) (2001) 11402-8. 
 
[172] P. Dhawan, A. Richmond, Role of CXCL1 in tumorigenesis of melanoma, 
Journal of leukocyte biology 72(1) (2002) 9-18. 
 
[173] P.D. Hsu, E.S. Lander, F. Zhang, Development and applications of CRISPR-
Cas9 for genome engineering, Cell 157(6) (2014) 1262-78. 
 
[174] N.A. Franken, H.M. Rodermond, J. Stap, J. Haveman, C. van Bree, Clonogenic 
assay of cells in vitro, Nature protocols 1(5) (2006) 2315-9. 
 
[175] G.P. Gupta, J. Massague, Cancer metastasis: building a framework, Cell 
127(4) (2006) 679-95. 
 
[176] A. Esquela-Kerscher, F.J. Slack, Oncomirs - microRNAs with a role in cancer, 
Nature reviews. Cancer 6(4) (2006) 259-69. 
 
[177] C. Varamo, M. Occelli, D. Vivenza, M. Merlano, C. Lo Nigro, MicroRNAs role 
as potential biomarkers and key regulators in melanoma, Genes, chromosomes & 
cancer 56(1) (2017) 3-10. 
 
[178] Y. Hao, X. Gu, Y. Zhao, S. Greene, W. Sha, D.T. Smoot, J. Califano, T.C. Wu, X. 
Pang, Enforced expression of miR-101 inhibits prostate cancer cell growth by 
modulating the COX-2 pathway in vivo, Cancer prevention research 4(7) (2011) 
1073-83. 
 
[179] Y. Ji, Y. He, L. Liu, X. Chong, Corrigendum to "MiRNA-26b regulates the 
expression of cyclooxygenase-2 in desferrioxamine-treated CNE cells" [FEBS Lett. 
584 (5) (2010) 961-967], FEBS letters 589(2) (2015) 277. 
 
[180] J. Li, X. Li, X. Kong, Q. Luo, J. Zhang, L. Fang, MiRNA-26b inhibits cellular 
proliferation by targeting CDK8 in breast cancer, International journal of clinical 
and experimental medicine 7(3) (2014) 558-65. 
 
[181] D. Li, J. Hu, H. Song, H. Xu, C. Wu, B. Zhao, D. Xie, T. Wu, J. Zhao, L. Fang, 
miR-143-3p targeting LIM domain kinase 1 suppresses the progression of triple-
negative breast cancer cells, American journal of translational research 9(5) 
(2017) 2276-2285. 
 
[182] Z. He, J. Yi, X. Liu, J. Chen, S. Han, L. Jin, L. Chen, H. Song, MiR-143-3p 
functions as a tumor suppressor by regulating cell proliferation, invasion and 
epithelial-mesenchymal transition by targeting QKI-5 in esophageal squamous cell 
carcinoma, Molecular cancer 15(1) (2016) 51. 
 
[183] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018, CA: a cancer journal 
for clinicians 68(1) (2018) 7-30. 
CHAPTER 6 
144 
 
[184] M. Martin, H. Wei, T. Lu, Targeting microenvironment in cancer 
therapeutics, Oncotarget 7(32) (2016) 52575-52583. 
 
[185] J. Cheng, X.M. Fan, Role of cyclooxygenase-2 in gastric cancer development 
and progression, World journal of gastroenterology 19(42) (2013) 7361-8. 
 
[186] Y. Higashi, T. Kanekura, T. Kanzaki, Enhanced expression of cyclooxygenase 
(COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by 
inhibiting COX-2 expression, International journal of cancer 86(5) (2000) 667-71. 
 
[187] T.D. Warner, F. Giuliano, I. Vojnovic, A. Bukasa, J.A. Mitchell, J.R. Vane, 
Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 
are associated with human gastrointestinal toxicity: a full in vitro analysis, 
Proceedings of the National Academy of Sciences of the United States of America 
96(13) (1999) 7563-8. 
 
[188] C. Patrono, Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs, 
Current cardiology reports 18(3) (2016) 25. 
 
[189] C. Waskewich, R.D. Blumenthal, H. Li, R. Stein, D.M. Goldenberg, J. Burton, 
Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors 
for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines, 
Cancer research 62(7) (2002) 2029-33. 
 
[190] S. Zelenay, A.G. van der Veen, J.P. Bottcher, K.J. Snelgrove, N. Rogers, S.E. 
Acton, P. Chakravarty, M.R. Girotti, R. Marais, S.A. Quezada, E. Sahai, C. Reis e 
Sousa, Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity, 
Cell 162(6) (2015) 1257-70. 
 
[191] W. Elsheikh, R.W. Blackler, K.L. Flannigan, J.L. Wallace, Enhanced 
chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug 
(ATB-346) in experimental colorectal cancer, Nitric oxide : biology and chemistry 
41 (2014) 131-7. 
 
[192] M. Paul-Clark, W. Elsheikh, N. Kirkby, M. Chan, P. Devchand, T.A. Agbor, K.L. 
Flannigan, C. Cheadle, M. Freydin, A. Ianaro, J.A. Mitchell, J.L. Wallace, Profound 
Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the 
APCMin/+ Mouse Model of Intestinal Tumorigenesis, PloS one 11(2) (2016) 
e0147289. 
 
[193] S.M. Kantrow, A.S. Boyd, D.L. Ellis, L.B. Nanney, A. Richmond, Y. Shyr, J.B. 
Robbins, Expression of activated Akt in benign nevi, Spitz nevi and melanomas, 
Journal of cutaneous pathology 34(8) (2007) 593-6. 
 
[194] G. Maurer, B. Tarkowski, M. Baccarini, Raf kinases in cancer-roles and 
therapeutic opportunities, Oncogene 30(32) (2011) 3477-88. 
 
[195] H.C. Dan, M. Sun, S. Kaneko, R.I. Feldman, S.V. Nicosia, H.G. Wang, B.K. 
Tsang, J.Q. Cheng, Akt phosphorylation and stabilization of X-linked inhibitor of 
apoptosis protein (XIAP), The Journal of biological chemistry 291(43) (2016) 
22846. 
REFERENCES 
145 
 
[196] T. Tanaka, Z. Bai, Y. Srinoulprasert, B.G. Yang, H. Hayasaka, M. Miyasaka, 
Chemokines in tumor progression and metastasis, Cancer science 96(6) (2005) 
317-22. 
 
[197] C. Li, Y. Yin, X. Liu, X. Xi, W. Xue, Y. Qu, Non-small cell lung cancer associated 
microRNA expression signature: integrated bioinformatics analysis, validation and 
clinical significance, Oncotarget 8(15) (2017) 24564-24578. 
 
[198] F. Wang, J. Liu, Y. Zou, Y. Jiao, Y. Huang, L. Fan, X. Li, H. Yu, C. He, W. Wei, H. 
Wang, G. Sun, MicroRNA-143-3p, up-regulated in H. pylori-positive gastric cancer, 
suppresses tumor growth, migration and invasion by directly targeting AKT2, 
Oncotarget 8(17) (2017) 28711-28724. 
 
[199] H. Zhang, W. Li, Dysregulation of micro-143-3p and BALBP1 contributes to 
the pathogenesis of the development of ovarian carcinoma, Oncology reports 
36(6) (2016) 3605-3610. 
 
[200] X. Chen, K. Shi, Y. Wang, M. Song, W. Zhou, H. Tu, Z. Lin, Clinical value of 
integrated-signature miRNAs in colorectal cancer: miRNA expression profiling 
analysis and experimental validation, Oncotarget 6(35) (2015) 37544-56. 
 
[201] O. Slaby, R. Laga, O. Sedlacek, Therapeutic targeting of non-coding RNAs in 
cancer, The Biochemical journal 474(24) (2017) 4219-4251. 
 
[202] J. Lu, G. Getz, E.A. Miska, E. Alvarez-Saavedra, J. Lamb, D. Peck, A. Sweet-
Cordero, B.L. Ebert, R.H. Mak, A.A. Ferrando, J.R. Downing, T. Jacks, H.R. Horvitz, 
T.R. Golub, MicroRNA expression profiles classify human cancers, Nature 
435(7043) (2005) 834-8. 
 
[203] H. Shao, L. Cai, M. Moller, B. Issac, L. Zhang, M. Owyong, A.E. Moscowitz, R. 
Vazquez-Padron, F. Radtke, Z.J. Liu, Notch1-WISP-1 axis determines the regulatory 
role of mesenchymal stem cell-derived stromal fibroblasts in melanoma 
metastasis, Oncotarget 7(48) (2016) 79262-79273. 
 
[204] G.G. McGill, M. Horstmann, H.R. Widlund, J. Du, G. Motyckova, E.K. 
Nishimura, Y.L. Lin, S. Ramaswamy, W. Avery, H.F. Ding, S.A. Jordan, I.J. Jackson, 
S.J. Korsmeyer, T.R. Golub, D.E. Fisher, Bcl2 regulation by the melanocyte master 
regulator Mitf modulates lineage survival and melanoma cell viability, Cell 109(6) 
(2002) 707-18. 
 
[205] H. Mirzaei, S. Gholamin, S. Shahidsales, A. Sahebkar, M.R. Jaafari, H.R. 
Mirzaei, S.M. Hassanian, A. Avan, MicroRNAs as potential diagnostic and 
prognostic biomarkers in melanoma, European journal of cancer 53 (2016) 25-32. 
 
